CN102283910A - Chinese medicinal composition with anti-depression effect and preparation and preparation method thereof - Google Patents
Chinese medicinal composition with anti-depression effect and preparation and preparation method thereof Download PDFInfo
- Publication number
- CN102283910A CN102283910A CN2011102229562A CN201110222956A CN102283910A CN 102283910 A CN102283910 A CN 102283910A CN 2011102229562 A CN2011102229562 A CN 2011102229562A CN 201110222956 A CN201110222956 A CN 201110222956A CN 102283910 A CN102283910 A CN 102283910A
- Authority
- CN
- China
- Prior art keywords
- ethanol
- extract
- radix
- preparation
- paeoniae alba
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
技术领域 technical field
本发明属于中药领域,尤其涉及一种抗抑郁作用的中药有效部位组合物,以及含该组合物的中药制剂,以及该组合物的制备方法。The invention belongs to the field of traditional Chinese medicine, and in particular relates to a composition of effective part of traditional Chinese medicine with antidepressant effect, a traditional Chinese medicine preparation containing the composition, and a preparation method of the composition.
背景技术 Background technique
抑郁症(Depression)是由各种原因引起的以抑郁为主要症状的一组心境障碍(MoodDisorders)或情感性障碍(Affective Disorders),是一组以抑郁心境自我体验为中心的临床症状群或状态,是一种不愉快的心境体验。抑郁症是一种影响到躯体、情绪和思维的精神科常见疾病,它严重影响到人的进食、睡眠规律;影响个人对自己的感觉、思考问题的方式。常表现为:丧失愉快、精力减退、精神运动迟滞或激越、自卑或有内疚感、思考能力下降、有自杀倾向或自伤行为、睡眠障碍、食欲减退和性欲减退等症状。Depression is a group of mood disorders (Mood Disorders) or affective disorders (Affective Disorders) caused by various reasons with depression as the main symptom. It is a group of clinical symptoms or states centered on self-experience of depressed mood. , is an unpleasant mood experience. Depression is a common psychiatric disease that affects the body, emotions, and thinking. It seriously affects people's eating and sleeping patterns; it affects how individuals feel about themselves and how they think about problems. Symptoms are: loss of pleasure, decreased energy, psychomotor retardation or agitation, low self-esteem or guilt, decreased thinking ability, suicidal tendencies or self-injurious behavior, sleep disturbance, loss of appetite and libido and other symptoms.
据世界卫生组织发表的《2002年世界卫生组织报告》,抑郁症已位居世界10大疾病的第4位,预计到2020年将跃至第2,居心肌梗死之后,癌症之前。WHO的数字显示,当前全球的抑郁症患者有8500万,预计到2005年其发病率将达到总人口的10%。据最新资料显示,精神障碍在疾病总负担中的排名已经跃居首位,而上海的抑郁症患者已占总人口5%以上。在北美地区和欧盟各国,抑郁症可造成每年高达1500亿美元的损失。同时抑郁症患者的自杀率高达15%。但是由于认识不足,绝大部分的抑郁症患者没有得到正确的诊断治疗。因此增强对抑郁症的认识,加强抗抑郁药的研究,保证社会健康发展有着十分重要的意义,并将产生较大的经济效益和社会效益。According to the "2002 World Health Organization Report" issued by the World Health Organization, depression has ranked fourth among the top ten diseases in the world, and it is expected to jump to the second place by 2020, after myocardial infarction and before cancer. The figures of WHO show that there are 85 million depression patients in the world at present, and its incidence rate is expected to reach 10% of the total population by 2005. According to the latest data, the ranking of mental disorders in the total burden of disease has jumped to the first place, and the depression patients in Shanghai have accounted for more than 5% of the total population. Depression costs up to $150 billion a year in North America and the European Union. At the same time, the suicide rate of depressed patients is as high as 15%. However, due to lack of awareness, the vast majority of depression patients have not received correct diagnosis and treatment. Therefore, it is of great significance to enhance the understanding of depression, strengthen the research of antidepressants, and ensure the healthy development of society, and will produce greater economic and social benefits.
抑郁症的治疗方法可分为药物治疗、精神疗法、社会疗法和行为疗法。高发且难以根治的抑郁症正在逐渐构筑可观的抗抑郁药市场,这正是近年来国内外对中枢神经系统药物研究开发特别活跃的主要原因之一。据统计,抗抑郁药物在美国2000年约占中枢神经系统药品市场的40%以上。抗抑郁药市场的销售额1995年为30亿美元,1998年为60亿美元,呈逐年大幅上升趋势。2000年世界药品市场销售额排名前10位的治疗药物中,抗抑郁药年销售额达134亿美元,占全球销售份额的4.2%,位居第3;销售额增长率为18%,位居第5。在国内,对北京、上海、广州、重庆、武汉、南京、成都、杭州等8大城市1997年~2002年抗抑郁药使用情况的调查表明,我国抗抑郁药物市场在迅速增长。可以预见,未来抗抑郁药物市场的潜力会相当大,世界卫生组织自2001年以来已把关注精神疾病问题作为它的主要任务之一,中国卫生部门也已将抑郁症列为今后的防治重点。Treatment for depression can be divided into medication, psychotherapy, social therapy, and behavioral therapy. The high-incidence and difficult-to-cure depression is gradually building a considerable antidepressant market, which is one of the main reasons for the particularly active research and development of central nervous system drugs at home and abroad in recent years. According to statistics, antidepressant drugs accounted for more than 40% of the central nervous system drug market in the United States in 2000. The sales of the antidepressant drug market was 3 billion US dollars in 1995 and 6 billion US dollars in 1998, showing a sharp upward trend year by year. In 2000, among the top 10 therapeutic drugs in the world drug market sales, the annual sales of antidepressants reached 13.4 billion US dollars, accounting for 4.2% of the global sales share, ranking third; the sales growth rate was 18%, ranking first. number 5. In China, a survey on the use of antidepressants in eight major cities including Beijing, Shanghai, Guangzhou, Chongqing, Wuhan, Nanjing, Chengdu, and Hangzhou from 1997 to 2002 shows that the market for antidepressants in my country is growing rapidly. It can be predicted that the potential of the antidepressant drug market in the future will be quite large. Since 2001, the World Health Organization has taken attention to mental illness as one of its main tasks, and the Chinese health department has also listed depression as the focus of future prevention and treatment.
临床上抗抑郁多采用化学药物进行治疗。目前常用的有单胺氧化酶抑制剂(MAGI),如苯乙肼,苯异丙肼等。三环类抗抑郁药(TCA),如去甲丙咪嗪、阿米替林、去甲替林等。杂环类抗抑郁药(HCA),如马普替林、米安色林等。选择性的5-羟色胺再摄取抑制剂(SSRI),如氟西汀、帕罗西汀、舍曲林、西酞普莱等。5-羟色胺和去甲肾上腺素再摄取抑制剂(SNRI),文拉法辛、度洛西汀、米那普仑等。去甲肾上腺素和特定5-羟色胺再摄取抑制剂(NaSSA),如米氮平等。除以上几大类外,还有不少具有一定抗抑郁作用的药物用于临床,如调整多种中枢神经递质传导功能的药物、5-羟色胺受体阻断剂、多巴胺再摄取阻滞剂等,同时有些抗精神病药也有抗抑郁作用,可作辅助治疗。Clinically antidepressants are mostly treated with chemical drugs. Currently commonly used monoamine oxidase inhibitors (MAGI), such as phenelzine, phenprohydrazine and so on. Tricyclic antidepressants (TCAs), such as desipramine, amitriptyline, nortriptyline, etc. Heterocyclic antidepressants (HCA), such as maprotiline, mianserin, etc. Selective serotonin reuptake inhibitors (SSRIs), such as fluoxetine, paroxetine, sertraline, citalopram, etc. Serotonin and norepinephrine reuptake inhibitors (SNRI), venlafaxine, duloxetine, milnacipran, etc. Norepinephrine and specific serotonin reuptake inhibitors (NaSSAs), such as mirtazapine. In addition to the above categories, there are many drugs with certain antidepressant effects that are used clinically, such as drugs that adjust the conduction function of various central neurotransmitters, serotonin receptor blockers, and dopamine reuptake blockers. etc. At the same time, some antipsychotics also have antidepressant effects and can be used as adjuvant therapy.
尽管西药抗抑郁的前景较好,但是发病机制的复杂性和用药的单一性,使得抗抑郁治疗处于一种明显的不对称局面。抗抑郁药物治疗现存的问题是:第一,对一些难治性抑郁症不能奏效;第二,抑郁药治疗中不良反应繁多,如体重增加、性功能障碍、失眠、嗜睡、虚弱等,还具有撤药综合征,不利于长期服用;第三,起效缓慢,大约需要2-3周才能产生效果,不利于抓住时机,控制症状,使本来依从性差的患者丧失信心;第四,抑郁症治愈后的复发率仍然较高。因此国内外在抗抑郁药的研制与开发方面越来越注重天然药物,特别是有两千多年历史的中药。Although the antidepressant prospect of Western medicine is good, the complexity of the pathogenesis and the singleness of the medication make the antidepressant treatment in an obvious asymmetrical situation. The existing problems of antidepressant drug treatment are: first, it cannot be effective for some refractory depression; Withdrawal syndrome is not conducive to long-term use; third, the onset is slow, and it takes about 2-3 weeks to produce results, which is not conducive to seizing the opportunity, controlling symptoms, and making patients with poor compliance lose confidence; fourth, depression The recurrence rate after cure is still high. Therefore, the research and development of antidepressants at home and abroad pay more and more attention to natural medicines, especially traditional Chinese medicines with a history of more than two thousand years.
目前研究较多的有明确抗抑郁作用的古方逍遥散、四逆散、柴胡桂枝汤、柴胡疏肝散、大柴胡汤、平肝开郁汤、宣郁通经汤等,经验方疏郁达神汤、解郁合欢汤、柴芍六君子汤、柴桂温胆定志汤等,都以柴胡、白芍为方中主药。据统计,《伤寒论》42首抗抑郁效方中,柴胡出现23次,芍药出现16次,为疏肝解郁和活血补血出现频率最高的单味药物。中医认为,常见的抑郁症中医证型分别是:肝郁气滞证、肝郁脾虚证、肝郁痰阻证、心脾两虚证和肝郁血瘀证。其中又以肝郁气滞证最为常见症。可见,选择柴胡、白芍作为抗抑郁中药基础方,具有临床实际意义。At present, there are more ancient prescriptions Xiaoyao San, Sini San, Chaihu Guizhi Decoction, Chaihu Shugan San, Da Chaihu Decoction, Pinggan Kaiyu Decoction, Xuanyu Tongjing Decoction, etc., which have clear antidepressant effects. Dashen Decoction, Jieyu Hehuan Decoction, Chai Shao Liu Jun Zi Decoction, Chai Gui Wen Dan Ding Zhi Decoction, etc., all use Bupleurum and Bai Shao as the main ingredients in the prescription. According to statistics, among the 42 antidepressant prescriptions in "Treatise on Febrile Diseases", Bupleurum appears 23 times, and Peony appears 16 times. They are single herbs with the highest frequency of soothing the liver, relieving depression and promoting blood circulation. Traditional Chinese medicine believes that the common TCM syndrome types of depression are: liver depression and qi stagnation syndrome, liver depression and spleen deficiency syndrome, liver depression and phlegm obstruction syndrome, heart and spleen deficiency syndrome, and liver depression and blood stasis syndrome. Among them, the most common disease is liver-qi stagnation syndrome. It can be seen that choosing Bupleurum and Baishao as the basic prescription of antidepressant traditional Chinese medicine has clinical significance.
发明内容 Contents of the invention
为了克服治疗抑郁症的西药不良反应多,起效慢,复发率高的缺陷,本发明的目的之一是提供一种抗抑郁作用的中药有效部位组合物及中药制剂,其疗效显著、纯度高、服用量小、副反应少。In order to overcome the defects of many adverse reactions, slow onset and high relapse rate of Western medicine for the treatment of depression, one of the purposes of the present invention is to provide a Chinese medicine effective part composition and Chinese medicine preparation with antidepressant effect, which has remarkable curative effect and high purity. , small dosage, less side effects.
本发明的目的之二是提供一种上述中药组合物的制备方法,其工艺稳定,操作可行,提取率高,纯度高,环境污染小,适合工业化生产。The second object of the present invention is to provide a preparation method of the above-mentioned traditional Chinese medicine composition, which has stable process, feasible operation, high extraction rate, high purity, low environmental pollution, and is suitable for industrial production.
为了达到上述的目的,本发明采用了以下的技术方案:In order to achieve the above-mentioned purpose, the present invention has adopted following technical scheme:
一种抗抑郁作用的中药组合物,由下列重量份的提取物制成:白芍提取物1-10份,柴胡提取物1-10份。The traditional Chinese medicine composition with antidepressant effect is prepared from the following extracts in parts by weight: 1-10 parts of Radix Paeoniae Alba extract and 1-10 parts of Bupleurum bupleuri extract.
作为优选,所述白芍提取物为9份,柴胡提取物为1份。Preferably, the Radix Paeoniae Alba extract is 9 parts, and the Radix Bupleurum extract is 1 part.
一种中药制剂,由如上所述的中药组合物制成,其剂型为口服液、片剂、胶囊剂、滴丸剂和颗粒剂中的任意一种,优选为胶囊剂。A traditional Chinese medicine preparation is made from the traditional Chinese medicine composition as described above, and its dosage form is any one of oral liquid, tablet, capsule, drop pill and granule, preferably capsule.
一种中药制剂,由如上所述的中药组合物加入等重量的淀粉,混合均匀,灌装于胶囊中制得,胶囊中含芍药苷的含量不得少于7.50%,白芍总皂苷的含量不得少于25.0%,柴胡皂苷d的含量不得少于0.50%,柴胡总皂苷的含量不得少于2.50%。A traditional Chinese medicine preparation, which is prepared by adding equal weight of starch to the above traditional Chinese medicine composition, mixing evenly, and filling it in capsules. The content of paeoniflorin in the capsules must not be less than 7.50%, and the content of total saponins of paeony must not be less than 7.5%. less than 25.0%, the content of saikosaponin d shall not be less than 0.50%, and the content of total saikosaponins shall not be less than 2.50%.
一种中药组合物的制备方法,包括如下步骤:A preparation method of a Chinese medicine composition, comprising the steps of:
1)制备白芍提取物:取白芍饮片,分别加入8倍量70%乙醇,提取3次,每次2小时,所得提取液减压回收乙醇,浓缩至2.0g生药/ml,取1BV体积的浓缩液,以1BV/小时的流速过AB-8大孔吸附树脂,静置2小时后,用去离子水以1BV/小时的流速清洗至流出液无色,用10BV 70%乙醇以2BV/小时的速度进行洗脱,收集洗脱液,减压回收乙醇,浓缩至浸膏,60℃真空干燥,取出,粉碎,得到白芍提取物;1) Preparation of Radix Paeoniae Alba Extract: Take Radix Paeoniae Alba, add 8 times the amount of 70% ethanol respectively, extract 3 times, each time for 2 hours, recover ethanol from the obtained extract under reduced pressure, concentrate to 2.0g crude drug/ml, and take 1BV volume The concentrated solution is passed through the AB-8 macroporous adsorption resin at a flow rate of 1BV/hour, and after standing for 2 hours, it is washed with deionized water at a flow rate of 1BV/hour until the effluent is colorless, and then washed with 10BV 70% ethanol at 2BV/ Carry out elution at a speed of one hour, collect the eluate, recover ethanol under reduced pressure, concentrate to extract, vacuum dry at 60°C, take out, pulverize, and obtain Radix Paeoniae Alba extract;
2)制备柴胡提取物:取柴胡饮片,分别加入10倍量含1.0%碳酸钠的80%乙醇,加热回流提取3次,每次1.5小时,合并提取液;所得的提取液减压回收乙醇,浓缩至0.2g生药/ml,量取1BV提取液,以1BV/小时的流速过AB-8大孔吸附树脂,静置2小时后,用去离子水10BV以1BV/小时的流速洗脱,弃去洗脱液,再用20%乙醇10BV以1BV/小时的流速清洗,弃去清洗液,用70%乙醇10BV以2BV/小时的速度洗脱,收集洗脱液,减压回收乙醇,浓缩至浸膏,60℃真空干燥,取出,粉碎,得到柴胡提取物;2) Preparation of Bupleurum extract: take Bupleurum decoction pieces, add 10 times the amount of 80% ethanol containing 1.0% sodium carbonate respectively, heat and reflux extraction for 3 times, each time for 1.5 hours, and combine the extracts; the obtained extracts are recovered under reduced pressure Ethanol, concentrated to 0.2g crude drug/ml, measure 1BV extract, pass through AB-8 macroporous adsorption resin at a flow rate of 1BV/hour, let it stand for 2 hours, and elute with 10BV of deionized water at a flow rate of 1BV/hour , discard the eluent, then wash with 20% ethanol 10BV at a flow rate of 1BV/hour, discard the cleaning solution, and use 70% ethanol 10BV to elute with a speed of 2BV/hour, collect the eluent, and reclaim ethanol under reduced pressure, Concentrate to extract, vacuum dry at 60°C, take out, pulverize to obtain Bupleurum extract;
3)制备组合物:按白芍提取物∶柴胡提取物为9∶1的重量配比,称取上述两种提取物,混合均匀制成上所述的中药组合物。3) Preparation of composition: according to the weight ratio of Radix Paeoniae Alba extract:Bupleurum extract 9:1, the above two extracts were weighed and mixed uniformly to prepare the above-mentioned traditional Chinese medicine composition.
其中,“70%乙醇”即为浓度为70%的乙醇溶液,“80%乙醇”、“20%乙醇”同理,“含1.0%碳酸钠的80%乙醇”即为浓度为80%的乙醇溶液中含有重量百分比为1.0%的碳酸钠;“6倍量70%乙醇”即为重量为饮片重量的6倍的浓度为70%的乙醇溶液,“8倍量、10倍量”同理。Among them, "70% ethanol" is an ethanol solution with a concentration of 70%, "80% ethanol" and "20% ethanol" are the same, "80% ethanol containing 1.0% sodium carbonate" is an ethanol solution with a concentration of 80% The solution contains 1.0% sodium carbonate by weight; "6 times the amount of 70% ethanol" is a 70% ethanol solution whose weight is 6 times the weight of the decoction pieces, and "8 times the amount and 10 times the amount" is the same.
本发明所用白芍为毛茛科植物芍药Paeonia lactiflora Pall.的干燥根,以补养阴血见长,又能柔肝平肝,缓急止痛,清解虚热。柴胡为狭叶柴胡Bupleurum scorzonerifolium Willd.的干燥根,轻清,长于疏达走窜,辛散善行,为疏肝理气,开郁结退热之佳品,二药相伍,柴胡得白芍之柔,行肝气而不致疏泄太过,耗肝之体;白芍得柴胡之散,补肝血而不致郁遏气阴,碍肝之用,共奏疏肝、解郁和解表里止痛之功。既能疏肝解郁,以治肝用之不达,又能柔肝益阴以补肝体,为体用兼顾之最佳配伍。The Radix Paeoniae Alba used in the present invention is the dry root of Paeonia lactiflora Pall., a plant of the Ranunculaceae family. It is good at nourishing yin and blood, and can soften the liver and calm the liver, relieve spasm and relieve pain, and clear away asthenic heat. Bupleurum is the dry root of Bupleurum scorzonerifolium Willd., light and clear, good at loosening and walking, pungent and good at doing, it is a good product for soothing the liver and regulating qi, opening depression and reducing fever. The softness can promote the liver qi without dredging too much, which consumes the body of the liver; the powder of Bupleurum from white peony root can nourish the liver blood without causing stagnation and stagnation of qi and yin, which hinder the function of the liver. merit. It can not only soothe the liver and relieve stagnation, so as to treat the insufficiency of the liver, but also soften the liver and replenish yin to nourish the liver and body. It is the best combination for both body and function.
本发明经现代制药工艺提取柴胡总皂苷和白芍总皂苷,按一定配伍比例制成解郁胶囊,具有明确的药用有效部位和明确的疗效,制备方法简单,操作可行,且环境污染小,适合工业化生产,能取得较好的社会效益和经济效益。The invention extracts total saponins of Bupleuri and total saponins of paeony through modern pharmaceutical technology, and makes Jieyu capsules according to a certain compatibility ratio, has clear medicinal effective parts and clear curative effects, simple preparation method, feasible operation, and less environmental pollution , suitable for industrial production, and can achieve better social and economic benefits.
具体实施方式 Detailed ways
以下是对抗抑郁作用的中药有效部位组合物及其制备方法中各因素的分析和实验:The following is the analysis and experiment of each factor in the effective part composition of traditional Chinese medicine for antidepressant effect and its preparation method:
一、白芍提取物制备:1. Preparation of Radix Paeoniae Alba Extract:
1、白芍总皂苷提取工艺优选1. Optimization of Extraction Process of Total Saponins of Paeoniae Alba
白芍的有效成分为芍药苷、白芍苷、氧化芍药苷和苯甲酞芍药苷等单萜类化合物,简称白芍总皂苷。影响白芍总皂苷提取的因素有乙醇浓度、乙醇用量(体积重量比,即乙醇体积与药材重量的比值)、提取时间、提取次数,本实验采用L18(37)正交设计和单因素考察相结合的方法,测定白芍提取物中白芍总皂苷和芍药苷的含量,并以白芍总皂苷和芍药苷含量的加权分数作为评价指标,优选了白芍总皂苷提取工艺,见表1至表5。The active ingredients of Radix Paeoniae Alba are monoterpenoids such as paeoniflorin, paeoniflorin alba, oxidized paeoniflorin and paeoniflorin benzophthalein, referred to as total saponins of paeony. Factors affecting the extraction of total saponins of Paeoniae Alba include ethanol concentration, ethanol dosage (volume to weight ratio, that is, the ratio of ethanol volume to medicinal material weight), extraction time, and extraction times. This experiment adopts L 18 (3 7 ) orthogonal design and single factor Investigate the combined method, measure the content of total saponins of white paeony and paeoniflorin in the extract of Radix Paeoniae Alba, and take the weighted fraction of total saponins of paeony and paeoniflorin as the evaluation index, optimize the extraction process of total saponins of paeony, see table 1 to Table 5.
表1白芍皂苷提取实验设计表Table 1 Paeony saponin extraction experimental design table
表2实验计划表Table 2 Experiment plan
分别按上述实验设计进行提取,滤过,合并滤液,定容至一定的体积。测定提取液中白芍总皂苷和芍药苷的含量,结果见表3。According to the above experimental design, extract, filter, combine the filtrates, and dilute to a certain volume. The content of total saponins and paeoniflorin in the extract was determined, and the results are shown in Table 3.
表3各提取液中白芍总皂苷及芍药苷的含量Table 3 Contents of total saponins of paeony and paeoniflorin in each extract
以白芍总皂苷及芍药苷的含量为指标进行加权评分,公式如下:The content of total saponins of paeony and paeoniflorin is used as the index to carry out weighted scoring, and the formula is as follows:
将分值进行正交分析见表4: Orthogonal analysis of the scores is shown in Table 4:
表4直观分析表Table 4 visual analysis table
表5方差分析表Table 5 variance analysis table
结果表明,提取次数有显著性差异,从直观分析表看出,乙醇浓度为70%,用量为8倍量,每次2小时,提取效果最佳,因此将该条件固定,对提取3次和4次进行比较,结果表明,提取3次与提取4次的效果相差不大,故确定提取次数为3次。The result shows that there is a significant difference in the number of extractions. From the visual analysis table, the ethanol concentration is 70%, and the consumption is 8 times the amount, and the extraction effect is the best for each 2 hours. Therefore, this condition is fixed. The comparison of 4 times shows that the effect of extraction 3 times is not much different from that of 4 times, so the number of times of extraction is determined to be 3 times.
验证试验:取白芍饮片200g,共3份,置10000ml圆底烧瓶中,加入8倍量70%乙醇,3份提取3次,3份提取4次,每次2小时,滤过,合并滤液,滤液定容至6000ml,测定提取液中白芍总皂苷及芍药苷的含量。结果表明芍药苷的平均含量21.49mg/g,白芍总皂苷的平均含量为42.90mg/g。与最佳工艺(第13组)的结果相近。Verification test: take 200g of Radix Paeoniae Alba decoction pieces, 3 parts in total, put them in a 10000ml round bottom flask, add 8 times the amount of 70% ethanol, extract 3 times for 3 parts, extract 4 times for 3 parts, 2 hours each time, filter, and combine the filtrates , the filtrate was settled to 6000ml, and the content of total saponins of paeony and paeoniflorin in the extract was measured. The results showed that the average content of paeoniflorin was 21.49mg/g, and the average content of total saponins of paeony was 42.90mg/g. Similar results to the best process (group 13).
最终确定白芍总皂苷的提取工艺为:取白芍饮片,分别加入8倍量,70%乙醇,提取3次,每次2小时。Finally, the extraction process of total saponins of Paeoniae Alba was determined as follows: take decoction pieces of Paeoniae Alba, add 8 times the amount, 70% ethanol, extract 3 times, 2 hours each time.
2、白芍总皂苷纯化工艺优选2. Optimal purification process of total saponins of paeony
静态吸附量的考察Investigation of Static Adsorption Capacity
称取各大孔吸附树脂5.0g(干重),树脂类型分别为:DM-130、860021、DM-2、DM-131、AB-8、D101,分别加入15ml白芍提取液(0.2g生药/ml),放置24小时。抽滤,滤液定容至25ml,测定溶液中白芍总皂苷的含量,结果表明,AB-8大孔吸附树脂的静态吸附能力明显优于其它树脂,故选择AB-8大孔吸附树脂。Take by weighing 5.0g (dry weight) of large porous adsorption resin, resin types are respectively: DM-130, 860021, DM-2, DM-131, AB-8, D101, add 15ml Radix Paeoniae Alba extract (0.2g crude drug /ml), left for 24 hours. Suction filtration, filtrate constant volume to 25ml, measure the content of total saponins of paeony in the solution, the result shows, the static adsorption capacity of AB-8 macroporous adsorption resin is obviously better than other resins, so choose AB-8 macroporous adsorption resin.
最大动态吸附量的考察Investigation of the maximum dynamic adsorption capacity
称取已预处理的AB-8大孔吸附树脂80g(湿重),装柱(内径4cm,柱高26cm),取白芍提取液(2.0g生药/ml)50ml,以80ml/h(1BV)的速度上样,收集流出液。放置2小时后,加去离子水以80ml/h的速度洗脱,100ml/份收集,测定流出液及洗脱液中白芍总皂苷的含量。结果最大动态吸附量为相当于68.27ml上样溶液,每克干树脂可吸附白芍提取液2ml(2.0g生药/ml)。Take pretreated AB-8 macroporous adsorption resin 80g (wet weight), pack into a column (inner diameter 4cm, column height 26cm), get Radix Paeoniae Alba extract (2.0g crude drug/ml) 50ml, with 80ml/h (1BV ) at the speed of sample loading, and the effluent was collected. After standing for 2 hours, add deionized water to elute at a speed of 80ml/h, collect 100ml/part, and measure the content of total saponins of paeony in the effluent and eluent. Results The maximum dynamic adsorption capacity was equivalent to 68.27ml of sample solution, and 2ml of Radix Paeoniae Alba extract could be adsorbed per gram of dry resin (2.0g crude drug/ml).
洗脱预实验Elution Preliminary Experiment
将上述吸附白芍提取液的AB-8树脂柱分别用10%、20%、30%、40%、50%、70%乙醇各200ml以80ml/h的速度洗脱,50ml/份收集洗脱液,测定洗脱液中白芍总皂苷的含量。Use 200ml of 10%, 20%, 30%, 40%, 50%, and 70% ethanol to elute the above-mentioned AB-8 resin column of the Radix Paeoniae Alba extract at a speed of 80ml/h, and collect and elute with 50ml/part solution, and the content of total saponins of paeony in the eluate was determined.
结果表明,10%~70%乙醇洗脱液中均含有白芍总皂苷,可能是AB-8大孔吸附树脂对白芍总皂苷的吸附能力较差,选择其它树脂进行洗脱预试验,发现结果基本相同,原因可能是白芍总皂苷的极性范围较广,不同浓度的乙醇对其都有一定的洗脱能力,考虑白芍提取液上柱,用水除杂后,直接用一定浓度的乙醇进行洗脱,测定洗脱液中白芍总皂苷的含量,如达到60%,说明该方法可行。The results showed that the 10%-70% ethanol eluent contained total saponins of paeony, which may be due to the poor adsorption capacity of AB-8 macroporous resin for total saponins of paeony. Basically the same, the reason may be that the total saponins of Paeoniae Alba have a wide range of polarity, and different concentrations of ethanol have a certain eluting ability. Considering that the extract of Paeoniae Alba is applied to the column, after removing impurities with water, directly use a certain concentration of ethanol Carry out elution, measure the content of total saponins of paeony in the eluent, if it reaches 60%, it shows that the method is feasible.
取已预处理的AB-8大孔吸附树脂80g(湿重),装柱(内径4cm,柱高20cm),取白芍提取液80ml,以80ml/h的速度上样,收集流出液,放置2小时后,加去离子水洗脱至流出液基本无色,再用70%乙醇200ml以80ml/h的速度洗脱,50ml/份收集洗脱液,测定洗脱液中苯甲酸的含量,结果表明,第一份洗脱液中不含白芍总皂苷,其余三份洗脱液中白芍总皂苷的含量均大于60%,故该方法可行。Get 80g (wet weight) of pretreated AB-8 macroporous adsorption resin, pack into a column (inner diameter 4cm, column height 20cm), get Radix Paeoniae Alba extract 80ml, load the sample at a speed of 80ml/h, collect the effluent, place After 2 hours, add deionized water for elution until the effluent is substantially colorless, then use 70% ethanol 200ml for elution at a speed of 80ml/h, collect the eluent at 50ml/part, measure the content of benzoic acid in the eluent, The results showed that the first eluate contained no total saponins of paeony, and the contents of total saponins of paeony in the remaining three eluates were all greater than 60%, so the method was feasible.
上样速度的考察Inspection of loading speed
取已预处理的AB-8大孔吸附树脂80g(湿重),共三根,取白芍提取液100ml,分别以80ml/h、160ml/h、240ml/h的速度上样,收集流出液,放置2小时后,加去离子水以80ml/h(1BV/h)的速度洗脱至流出液颜色基本无变化,100ml/份收集洗脱液,测定流出液及洗脱液中苯甲酸的含量。结果表明,上柱速度为80ml/h的吸附量最大,故确定上柱速度为1BV/小时。Get the pretreated AB-8 macroporous adsorption resin 80g (wet weight), totally three, get Radix Paeoniae Alba extract 100ml, load the sample with the speed of 80ml/h, 160ml/h, 240ml/h respectively, collect the effluent, After standing for 2 hours, add deionized water to elute with a speed of 80ml/h (1BV/h) until the color of the effluent does not change substantially, collect the eluent at 100ml/part, measure the content of benzoic acid in the effluent and the eluent . The results show that the adsorption capacity is the largest when the column loading speed is 80ml/h, so the column loading speed is determined to be 1BV/hour.
上柱液浓度的考察Investigation on the concentration of upper column solution
取白芍提取液(2.0g生药/ml)100ml,共4份,分别稀释2、5、10、20倍,以80ml/小时的速度上样,收集流出液,放置2小时后,加去离子水800ml以80ml/h的速度洗脱,100ml/份收集,测定流出液和洗脱液中苯甲酸的含量。结果表明,不同浓度白芍提取液的吸附量基本相同,为缩短上样时间,故上柱液浓度选择(2.0g生药/ml)。Take 100ml of Radix Paeoniae Alba extract (2.0g crude drug/ml), 4 parts in total, dilute 2, 5, 10, and 20 times respectively, load the sample at a speed of 80ml/hour, collect the effluent, leave it for 2 hours, add deionized Water 800ml is eluted with the speed of 80ml/h, and 100ml/ part is collected, and measures the content of benzoic acid in effluent and eluent. The results showed that the adsorption capacity of Radix Paeoniae Alba extracts with different concentrations was basically the same. In order to shorten the sample loading time, the concentration of the column solution was selected (2.0g crude drug/ml).
洗脱剂浓度及用量的考察Investigation on the Concentration and Dosage of Eluent
取已预处理的AB-8大孔吸附树脂80g(干重),共三根,分别取白芍提取液80ml,以80ml/小时的速度上样,放置2小时后,加去离子水以80ml/h的速度洗脱至流出液颜色基本无变化,再分别用50%、60%、70%乙醇以80ml/h的速度洗脱至流出液颜色基本无变化,100ml/份收集洗脱液,测定洗脱液中苯甲酸的含量。结果表明,70%乙醇800ml,即10BV就能将白芍总皂苷基本洗脱完全,洗脱率为90.40%,故确定采用70%乙醇10BV作为洗脱剂。Get pretreated AB-8 macroporous adsorption resin 80g (dry weight), three in total, take 80ml of Radix Paeoniae Alba extract respectively, load the sample at a speed of 80ml/hour, after standing for 2 hours, add deionized water at 80ml/hour The speed of elution of h until the color of the effluent is basically unchanged, and then eluted with 50%, 60%, and 70% ethanol at a speed of 80ml/h until the color of the effluent is basically unchanged, and the eluate is collected at 100ml/part, and measured The content of benzoic acid in the eluent. The results showed that 800ml of 70% ethanol, that is, 10BV, could completely elute the total saponins of paeony, and the elution rate was 90.40%, so it was determined to use 70% ethanol 10BV as the eluent.
洗脱速度的考察The investigation of elution speed
取白芍提取液80ml(2.0g生药/ml),共3份,上样,放置2小时后,用去离子水洗脱至洗脱液颜色基本无变化,分别用70%乙醇10BV对三根柱子以1BV/h、2BV/h、3BVh、4BV/h的速度进行洗脱,弃去第一个100ml洗脱液液,其余以200ml/份收集,洗脱液,测定洗脱液中苯甲酸的含量。结果表明,速度为1BV/h和2BV/h的洗脱率相差不大,考虑到2BV/小时的效率较高,故确定洗脱速度为2BV/小时。Take 80ml of Radix Paeoniae Alba extract (2.0g crude drug/ml), a total of 3 parts, load the sample, and after standing for 2 hours, elute with deionized water until the color of the eluent does not change substantially, and use 70% ethanol 10BV to treat the three columns respectively. Carry out elution with the speed of 1BV/h, 2BV/h, 3BVh, 4BV/h, discard the first 100ml eluate liquid, all the other are collected with 200ml/ part, eluate, measure the content of benzoic acid in the eluate content. The results showed that the elution rates of 1BV/h and 2BV/h had little difference. Considering the higher efficiency of 2BV/h, the elution rate was determined to be 2BV/h.
径高比考察Aspect-to-Height Ratio Inspection
取三根层析柱,分别称取80g、160g、240g(湿重)经预处理的AB-8大孔吸附树脂,装柱,取白芍提取液80ml、160ml、240ml(2.0g生药/ml),以1BV/h的速度上样,放置2小时后,分别用水10BV、20%乙醇10BV洗脱,再用70%乙醇10BV洗脱,2BV/份收集70%乙醇洗脱液,测定洗脱液中苯甲酸的含量。结果表明,三种径高比的洗脱率基本一致,说明径高比对洗脱率影响不大。Take three chromatographic columns, weigh 80g, 160g, 240g (wet weight) pretreated AB-8 macroporous adsorption resin respectively, pack them into columns, and take 80ml, 160ml, 240ml of Radix Paeoniae Alba extract (2.0g crude drug/ml) , load the sample at a speed of 1BV/h, after standing for 2 hours, elute with 10BV of water, 10BV of 20% ethanol, and then elute with 10BV of 70% ethanol, collect 70% ethanol eluate at 2BV/part, and measure the eluate content of benzoic acid. The results showed that the elution rates of the three diameter-to-height ratios were basically the same, indicating that the diameter-to-height ratio had little effect on the elution rate.
验证实验Verification experiment
取经已处理的AB-8大孔吸附树脂,装柱(三根,内径9.1cm,高度70cm,保留体积1500ml),分别取1500ml白芍提取液(2.0g生药/ml)上样以1500ml/h的速度上样,放置2小时后,用去离子水以1500ml/小时的速度洗脱,弃去洗脱液,用70%乙醇15000ml以3000ml/小时的速度洗脱,收集洗脱液,减压回收乙醇,真空干燥,粉碎,得到3批白芍总皂苷,测定含量。结果表明,三批白芍总皂苷的得率基本一致,最高得率为78.89%,白芍总皂苷的含量也相近,该实验的重复性较好。Get the processed AB-8 macroporous adsorption resin, pack into columns (three, inner diameter 9.1cm, height 70cm, retention volume 1500ml), get 1500ml Radix Paeoniae Alba extract (2.0g crude drug/ml) loading sample with 1500ml/h respectively Load the sample at a high speed, after standing for 2 hours, elute with deionized water at a rate of 1500ml/hour, discard the eluent, elute with 15000ml of 70% ethanol at a rate of 3000ml/hour, collect the eluent, and recover under reduced pressure Ethanol, vacuum-dried, crushed to obtain 3 batches of total saponins of paeony, and the content was determined. The results showed that the yields of total saponins of paeony among the three batches were basically the same, the highest yield was 78.89%, and the contents of total saponins of paeony were also similar, so the repeatability of the experiment was good.
表6验证实验结果Table 6 verification experiment results
最终确定白芍总皂苷的纯化工艺为:取经预处理的AB-8大孔吸附树脂,装柱,取1BV白芍提取液(2.0g生药/ml)以1BV/h的速度上样,放置2小时后,用去离子水以1BV/h的速度洗脱至洗脱液无色,弃去洗脱液,用70%乙醇10BV以2BV/h的速度洗脱,收集洗脱液,减压回收乙醇,浓缩至浸膏,60℃真空干燥,取出,粉碎,得到白芍提取物。The final determination of the purification process of total saponins of Paeoniae Alba is as follows: take the pretreated AB-8 macroporous adsorption resin, pack it into a column, take 1BV Paeoniae Alba extract (2.0g crude drug/ml) and load it at a speed of 1BV/h, and place it for 2 Hours later, use deionized water to elute at a rate of 1BV/h until the eluate is colorless, discard the eluate, and use 70% ethanol 10BV to elute at a rate of 2BV/h, collect the eluate, and recover under reduced pressure Ethanol, concentrated to the extract, vacuum-dried at 60°C, taken out, crushed to obtain the Radix Paeoniae Alba extract.
二、柴胡提取物制备:2. Preparation of Bupleurum extract:
1、柴胡总皂苷提取工艺优选1. Optimization of extraction process of total saponins of Bupleurum chinensis
柴胡作为临床常用药,大多以煎煮法提取柴胡皂苷类成分,由于柴胡皂苷a、d化学结构均具不稳定性,遇酸或受热易分别降解生成活性较弱的次生苷b1、b2,因此随着提取时间的延长,柴胡皂苷a、d的量将逐渐降低,影响柴胡制剂的质量和临床疗效。目前国内关于柴胡提取工艺的文献报道较多,但多以柴胡皂苷a单独为指标进行考察,很少有同时考察柴胡皂苷a、d和柴胡总皂苷的文献报道。因此,本发明采用正交试验综合考察柴胡中柴胡皂苷a、d和柴胡总皂苷的含量,筛选最佳工艺。As a commonly used clinical medicine, Bupleurum bupleuri is mostly extracted from saikosaponins by decoction. Because the chemical structures of saikosaponins a and d are unstable, they are easily degraded by acid or heat to form secondary glycosides b1 with weaker activity. , b2, so with the prolongation of the extraction time, the amount of saikosaponin a, d will gradually decrease, affecting the quality and clinical efficacy of Bupleurum preparations. At present, there are many domestic literature reports on the extraction process of Bupleurum, but most of them use saikosaponin a alone as the index for investigation, and there are few literature reports on the simultaneous inspection of saikosaponin a, d and total saikosaponins. Therefore, the present invention adopts an orthogonal test to comprehensively investigate the contents of saikosaponins a, d and total saikosaponins in Bupleurum bupleuri, and screen the optimal process.
吸水率、吸醇率的考察Investigation on Water Absorption and Alcohol Absorption
取柴胡饮片50g,共2份,一份加入水300ml,一份加入50%乙醇300ml,放置至透心,滤过,测定吸水率、吸醇率。结果用水或50%乙醇提取时,分别应多加水1.8L/Kg或50%乙醇1.2L/Kg。Take 50g of bupleurum decoction pieces, 2 parts in total, add 300ml of water to one part, and 300ml of 50% ethanol in the other part, place until it penetrates the heart, filter, and measure the water absorption rate and alcohol absorption rate. Results When extracting with water or 50% ethanol, 1.8L/Kg of water or 1.2L/Kg of 50% ethanol should be added respectively.
提取溶剂的考察Investigation of extraction solvent
取柴胡饮片50g,共2份,一份加入水300ml,一份加50%乙醇300ml,加热回流提取3次,每次1小时,滤过,合并滤液,定容至1000ml,测定提取液中柴胡总皂苷的含量。结果表明50%乙醇的提取效果较水好。Take 50g of Bupleurum decoction pieces, a total of 2 parts, add 300ml of water to one part, add 300ml of 50% ethanol to one part, heat and reflux extraction 3 times, 1 hour each time, filter, combine the filtrates, dilute to 1000ml, measure the The content of total saponins of Bupleurum. The results showed that the extraction effect of 50% ethanol was better than that of water.
提取方式的考察Examination of extraction methods
取柴胡饮片50g,共2份,分别用50%的乙醇300ml 60℃温浸、85℃回流提取3次,每次1小时,滤过,合并滤液,定容至1000ml,测定提取液中柴胡总皂苷的含量。结果表明,加热回流提取的提取效果佳。Take 50g of Bupleurum decoction pieces, 2 parts in total, soak them in 50% ethanol 300ml at 60°C, and extract them at 85°C for 3 times, each time for 1 hour, filter, combine the filtrates, and dilute to 1000ml, measure the Chaihu in the extract. Content of total saponins. The results showed that the heating and reflux extraction had the best extraction effect.
加碱对提取效果的影响Influence of Adding Alkali on Extraction Effect
参考有关文献及《中国药典》2005年版一部,发现应在提取时加入一定量的碱,对加碱与不加碱提取进行比较。Referring to the relevant literature and the 2005 edition of the "Chinese Pharmacopoeia", it is found that a certain amount of alkali should be added during extraction, and the extraction with alkali and without alkali is compared.
取柴胡饮片50g,共2份,一份不加碱,一份加入5%碳酸钠提取,分别用50%乙醇300ml回流提取3次,每次1小时,滤过,合并滤液,定容至1000ml。测定提取液中柴胡总皂苷的含量。结果表明,加碱后总皂苷的含量有所增加,因此提取时应加入一定量的碱。Take 50g of Bupleurum decoction pieces, a total of 2 parts, one part without adding alkali, one part for extraction with 5% sodium carbonate, reflux extraction with 300ml of 50% ethanol for 3 times, each time for 1 hour, filter, combine the filtrates, and dilute to 1000ml. The content of total saponins in the extract was determined. The results showed that the content of total saponins increased after adding alkali, so a certain amount of alkali should be added during extraction.
正交设计考察柴胡总皂苷的提取工艺Orthogonal Design to Investigate the Extraction Process of Bupleurum Total Saponins
影响柴胡总皂苷提取的因素有乙醇浓度、乙醇用量、提取时间、提取次数以及碱的浓度(用量),本实验采用L18(37)正交设计,以柴胡皂苷a、d和柴胡总皂苷为指标,考察上述因素对柴胡皂苷提取的影响。实验设计表及结果见表7~9。Factors affecting the extraction of total saponins of Bupleurum include ethanol concentration, ethanol dosage, extraction time, extraction times and alkali concentration (dosage). This experiment adopts L 18 (3 7 ) Total saikosaponin was used as an index to investigate the influence of the above factors on the extraction of saikosaponin. See Tables 7-9 for the experimental design and results.
表7柴胡皂苷提取实验设计表Table 7 Saikosaponin extraction experimental design table
以柴胡总皂苷及柴胡皂苷d的含量为指标进行加权评分,公式如下:Taking the content of total saikosaponins and saikosaponin d as indicators to carry out weighted scoring, the formula is as follows:
表8直观分析表Table 8 visual analysis table
表9方差分析表Table 9 variance analysis table
结果表明,乙醇浓度和提取次数有显著性差异,因此确定乙醇浓度为80%,提取次数为3次,从直观分析表可以看出,提取时间1.5小时和2小时差别不大,故确定提取时间为1.5小时,随着乙醇用量的增加,柴胡总皂苷及柴胡皂苷d的含量有所增加,应对乙醇用量8倍量和10倍量进行比较。The results show that there is a significant difference between the concentration of ethanol and the number of times of extraction, so it is determined that the concentration of ethanol is 80%, and the number of times of extraction is 3 times. From the visual analysis table, it can be seen that there is little difference between the extraction time of 1.5 hours and 2 hours, so the extraction time is determined For 1.5 hours, with the increase of ethanol dosage, the contents of total saikosaponins and saikosaponin d increased, and the comparison should be made between 8 times and 10 times the amount of ethanol.
在提取过程中发现80%乙醇提取时,加入0.4%的无水碳酸钠不能全部溶解,应对80%乙醇提取时的碱用量进行考察。During the extraction process, it was found that the addition of 0.4% anhydrous sodium carbonate could not completely dissolve the 80% ethanol extraction, so the amount of alkali used in the 80% ethanol extraction should be investigated.
碱用量的考察Investigation of Alkali Dosage
分别称取柴胡饮片50g,置1000ml圆底烧瓶中,加入10倍量80%乙醇,并加入一定量的无水碳酸钠(以乙醇体积计),80℃水浴回流提取3次,每次1.5小时,滤过,合并滤液,提取液定容至1500ml。测定提取液中柴胡总皂苷及柴胡皂苷d的含量。结果表明,碱浓度为1.0%时柴胡皂苷a、d的含量达到最大,故确定碱浓度为1.0%。Weigh 50g of Bupleurum decoction pieces respectively, put them in a 1000ml round-bottomed flask, add 10 times the amount of 80% ethanol, and add a certain amount of anhydrous sodium carbonate (calculated by the volume of ethanol), and extract 3 times under reflux in a water bath at 80°C, each time 1.5 hour, filter, combine the filtrates, and extract the volume to 1500ml. The contents of total saikosaponins and saikosaponin d in the extract were determined. The results showed that the content of saikosaponin a and d reached the maximum when the alkali concentration was 1.0%, so the alkali concentration was determined to be 1.0%.
乙醇用量考察Investigation of ethanol consumption
取柴胡饮片500g,共2份,置10000ml圆底烧瓶中,分别加入8倍量、10倍量的含1.0%无水碳酸钠的80%乙醇,加热回流提取3次,每次1.5小时,滤过,合并滤液,滤液定容至15000ml,测定提取液中柴胡总皂苷及柴胡皂苷a、d的含量,实验平行2次。结果表明,乙醇用量为10倍量时,柴胡皂苷a、d及柴胡总皂苷的平均含量较8倍量乙醇高,故确定乙醇用量为10倍量。Take 500g of Bupleurum decoction pieces, 2 parts in total, put them in a 10000ml round bottom flask, add 8 times the amount and 10 times the amount of 80% ethanol containing 1.0% anhydrous sodium carbonate respectively, heat and reflux for extraction 3 times, each time for 1.5 hours, Filtrate, combine the filtrates, set the volume of the filtrate to 15000ml, measure the content of total saikosaponins and saikosaponins a and d in the extract, and perform the experiment twice in parallel. The results showed that when the amount of ethanol was 10 times, the average content of saikosaponin a, d and total saikosaponin was higher than that of 8 times the amount of ethanol, so the amount of ethanol was determined to be 10 times.
验证试验Verification test
取柴胡饮片500g,共3份,置10L圆底烧瓶中,分别加入10倍量80%乙醇,并加入1.0%碳酸钠,加热回流提取3次,每次1.5小时,滤过,合并滤液,滤液定容至15000ml,测定提取液中柴胡总皂苷及柴胡皂苷a、d的含量。结果平均含量为柴胡皂苷a的含量1.1221mg/g,柴胡皂苷d含量为4.1216mg/g,柴胡总皂苷的含量为50.64mg/g。与最佳工艺的结果相近。Take 500g of Bupleurum decoction pieces, 3 parts in total, put them in a 10L round bottom flask, add 10 times the amount of 80% ethanol and 1.0% sodium carbonate, heat and reflux for 3 times, each time for 1.5 hours, filter, and combine the filtrates, The filtrate was settled to 15000ml, and the content of total saikosaponins and saikosaponin a, d in the assay extract. Results The average content of saikosaponin a was 1.1221 mg/g, saikosaponin d was 4.1216 mg/g, and total saikosaponin was 50.64 mg/g. The result is close to that of the best process.
综上所述,确定柴胡总皂苷的提取工艺为:取柴胡饮片,分别加入10倍量含1.0%碳酸钠的80%乙醇,提取3次,每次1.5小时。To sum up, the extraction process of total saponins of Bupleuri is determined as follows: take Bupleurum decoction pieces, add 10 times the amount of 80% ethanol containing 1.0% sodium carbonate, and extract 3 times, 1.5 hours each time.
2、柴胡总皂苷纯化工艺优选2. Optimal purification process of total saponins of Bupleurum
采用大孔吸附树脂进行纯化,影响大孔吸附树脂纯化效果的因素有大孔吸附树脂的类型、上柱液浓度、上柱速度、洗脱剂的浓度、用量以及洗脱速度等。The macroporous adsorption resin is used for purification. The factors affecting the purification effect of the macroporous adsorption resin include the type of macroporous adsorption resin, the concentration of the column solution, the column loading speed, the concentration and dosage of the eluent, and the elution speed.
静态吸附量的考察Investigation of Static Adsorption Capacity
称取各大孔吸附树脂5.0g(干重),树脂类型分别为:DM-130、860021、DM-2、DM-131、AB-8、D101,分别加入15ml柴胡提取液(0.8g生药/ml),放置24小时。抽滤,滤液定容至25ml,测定溶液中柴胡总皂苷的含量。结果表明,AB-8大孔吸附树脂的静态吸附能力明显优于其它树脂。Take by weighing 5.0g (dry weight) of large porous adsorption resin, resin types are respectively: DM-130, 860021, DM-2, DM-131, AB-8, D101, add 15ml Bupleurum extract (0.8g crude drug /ml), left for 24 hours. Suction filtration, the filtrate was settled to 25ml, and the content of total saikosaponins in the solution was measured. The results show that the static adsorption capacity of AB-8 macroporous adsorption resin is obviously superior to other resins.
最大动态吸附量的考察Investigation of the maximum dynamic adsorption capacity
称取已预处理的AB-8树脂大孔吸附树脂20g(干重),装柱(内径4cm,柱高21cm),取柴胡提取液(0.8g生药/ml)50ml,加水稀释至200ml,以50ml/h(1BV/h)的速度上样,收集流出液。放置2小时后,加去离子水以50ml/h的速度洗脱,100ml/份收集,测定流出液及洗脱液中柴胡总皂苷的含量。最大动态吸附量为相当于177ml上样溶液,每克干树脂可吸附柴胡提取液88.5ml(0.8g生药/ml)。Weigh 20g (dry weight) of the pretreated AB-8 resin macroporous adsorption resin, pack it into a column (inner diameter 4cm, column height 21cm), take 50ml of Bupleurum radix extract (0.8g crude drug/ml), add water to dilute to 200ml, Load the sample at a rate of 50ml/h (1BV/h), and collect the effluent. After standing for 2 hours, add deionized water to elute at a speed of 50ml/h, collect 100ml/part, and measure the content of total saponins in the effluent and eluent. The maximum dynamic adsorption capacity is equivalent to 177ml of sample solution, and each gram of dry resin can absorb 88.5ml of Bupleurum extract (0.8g crude drug/ml).
洗脱预实验Elution Preliminary Experiment
将上述树脂柱分别用10%、20%、30%、40%、50%、70%乙醇各200ml以50ml/h的速度洗脱,50ml/份收集洗脱液,测定洗脱液中柴胡总皂苷的含量。结果表明,10%~40%乙醇洗脱液中不含有柴胡总皂苷,50%乙醇洗脱液中含有柴胡总皂苷,但含量较少,说明50%乙醇对柴胡总皂苷的洗脱能力较弱,而70%乙醇洗脱液中含有较大量的柴胡总皂苷,说明70%乙醇可以作为柴胡总皂苷的洗脱剂。The above resin column was eluted with 200ml of 10%, 20%, 30%, 40%, 50%, and 70% ethanol respectively at a speed of 50ml/h, and the eluate was collected at 50ml/part, and Bupleurum bupleuri in the eluate was measured. total saponin content. The results showed that the 10%-40% ethanol eluent did not contain Bupleurum saponins, and the 50% ethanol eluent contained Bupleurum saponins, but the content was less, indicating that 50% ethanol could effectively elute the total Bupleurum saponins. The ability is weak, and the eluent of 70% ethanol contains a large amount of total saikosides, indicating that 70% ethanol can be used as the eluent of total saikosaponins.
上柱液浓度的考察Investigation on the concentration of upper column solution
取柴胡提取液(0.8g生药/ml)50ml,共4份,分别稀释2、4、6、8倍,以50ml/小时(1BV/h)的速度上样,收集流出液,放置2小时后,加去离子水400ml以50ml/小时的速度洗脱,100ml/份收集,测定流出液和洗脱液中柴胡总皂苷的含量。结果表明,在柴胡提取液稀释4倍,即0.2g生药/ml时的吸附量最大,确定上柱液浓度为0.2g生药/ml。Take 50ml of Bupleurum extract (0.8g crude drug/ml), 4 parts in total, dilute 2, 4, 6, and 8 times respectively, load the sample at a speed of 50ml/hour (1BV/h), collect the effluent, and let it stand for 2 hours Afterwards, add deionized water 400ml to elute with the speed of 50ml/hour, 100ml/part is collected, measure the content of total saikosides in the effluent and the eluent. The results show that the adsorption capacity is the largest when the Bupleurum extract is diluted 4 times, that is, 0.2g crude drug/ml, and the concentration of the upper column solution is determined to be 0.2g crude drug/ml.
上柱液流速的考察Investigation of the flow rate of upper column liquid
取柴胡提取液(0.2g生药/ml)200ml,共4份,分别以50ml/h(1BV/h)、100ml/h(2BV/h)、150ml/h(3BV/h)、200ml/h(4BV/h)的速度上样,收集流出液,放置2小时后,加去离子水400ml以50ml/h的速度洗脱,100ml/份收集,测定流出液和洗脱液中柴胡总皂苷的含量。结果表明,上柱液流速为50ml/h(1BV/h)时,吸附量最大,故确定上柱液流速为1BV/h。Take Bupleurum extract (0.2g crude drug/ml) 200ml, totally 4 parts, respectively with 50ml/h (1BV/h), 100ml/h (2BV/h), 150ml/h (3BV/h), 200ml/h (4BV/h) speed sample loading, collect the effluent, after standing for 2 hours, add deionized water 400ml to elute at a speed of 50ml/h, collect 100ml/part, measure the total saponins in the effluent and eluent content. The results show that when the flow rate of the upper column liquid is 50ml/h (1BV/h), the adsorption capacity is the largest, so the flow rate of the upper column liquid is determined to be 1BV/h.
除杂溶液浓度的确定Determination of concentration of impurity removal solution
从洗脱预实验中可以看出水及10%~40%乙醇可以作为除杂溶液。取柴胡提取液(0.2g生药/ml)150ml(最大动态吸附量的80%)上样,放置2小时后,分别用水、10%乙醇、20%乙醇、30%乙醇、40%乙醇进行洗脱,至洗脱液呈浅黄透明基本无变化,100ml/份收集洗脱液,测定洗脱液中固形物的重量。结果表明,去离子水洗脱500ml(10BV)后,洗脱液颜色基本无变化,且固形物较少;10%及20%乙醇能除去一定的杂质,而30%、40%乙醇除去的杂质较少。并对直接用20%乙醇洗脱进行考察,结果表明,其固形物与分别用10%和20%乙醇洗脱的总量基本一致,故确定采用20%乙醇进行除杂,并考察了20%乙醇的用量,确定用量为500ml(10BV)。It can be seen from the pre-elution experiment that water and 10%-40% ethanol can be used as impurity removal solutions. Take 150ml of Bupleurum extract (0.2g crude drug/ml) (80% of the maximum dynamic adsorption capacity) and put it on the sample. After standing for 2 hours, wash with water, 10% ethanol, 20% ethanol, 30% ethanol, and 40% ethanol respectively. Take off until the eluate is light yellow and transparent, basically unchanged, collect the eluate at 100ml/part, and measure the weight of the solids in the eluate. The result shows that after deionized water elutes 500ml (10BV), the color of the eluent does not change substantially, and the solids are less; 10% and 20% ethanol can remove certain impurities, while 30%, 40% ethanol removes impurities less. And the direct elution with 20% ethanol is investigated, the result shows that its solid matter is basically consistent with the total amount eluted with 10% and 20% ethanol respectively, so it is determined to use 20% ethanol for impurity removal, and 20% ethanol has been investigated. The consumption of ethanol, confirm consumption is 500ml (10BV).
洗脱液浓度及用量的考察Investigation on the Concentration and Dosage of Eluent
取柴胡提取液(0.2g生药/ml)150ml,共3份,上样,放置2小时后,用去离子水10BV、20%乙醇10BV洗脱,分别用60%、70%、80%乙醇对三根柱子以1BV/h的速度进行洗脱,洗脱至洗脱液基本无色,100ml/份(2BV/份)收集洗脱液,测定洗脱液中柴胡总皂苷的含量。结果表明,70%乙醇、80%乙醇洗脱900ml(18BV)能将90%的柴胡总皂苷洗脱,而60%乙醇1100ml(22BV)只能洗脱83.92%的柴胡总皂苷,故确定采用70%乙醇作为洗脱剂。70%乙醇中,前10BV就能将其中83%的柴胡总皂苷洗脱,故确定洗脱剂用量为10BV。Take Bupleurum extract (0.2g crude drug/ml) 150ml, a total of 3 parts, load the sample, after standing for 2 hours, elute with 10BV of deionized water, 10BV of 20% ethanol, and wash with 60%, 70%, 80% ethanol respectively The three columns were eluted at a speed of 1BV/h until the eluate was substantially colorless, and the eluate was collected at 100ml/part (2BV/part), and the content of total saikosaponins in the eluate was measured. The result shows that 70% ethanol, 80% ethanol eluting 900ml (18BV) can wash out 90% of the total saponins of Bupleurum, and 1100ml (22BV) of 60% ethanol can only wash out the total saponins of 83.92%, so determine 70% ethanol was used as eluent. In 70% ethanol, the first 10BV can elute 83% of the total saikosaponins, so the amount of eluent is determined to be 10BV.
洗脱速度的考察The investigation of elution speed
取柴胡提取液(0.2g生药/ml)150ml,共3份,上样,放置2小时后,用去离子水10BV、20%乙醇10BV洗脱,分别用70%乙醇10BV对三根柱子以1BV/h、2BV/h、3BV/h、4BV/h的速度进行洗脱,100ml/份(2BV/份)收集洗脱液,测定洗脱液中柴胡总皂苷的含量。Take Bupleurum extract (0.2g crude drug/ml) 150ml, a total of 3 parts, load the sample, after standing for 2 hours, use deionized water 10BV, 20% ethanol 10BV to elute, respectively use 70% ethanol 10BV to three columns with 1BV The speed of /h, 2BV/h, 3BV/h, 4BV/h is eluted, and 100ml/ part (2BV/ part) collects eluate, measures the content of saikosaponin in eluate.
结果表明,速度为1BV/h的洗脱率为86.96%,速度为2BV/h的洗脱率为87.32%,速度为3BV/h的洗脱率为79.81%,速度为4BV/h的洗脱率为76.49%。速度为2BV/h的洗脱率最大,故确定洗脱速度为2BV/h。The results showed that the elution rate of 1BV/h was 86.96%, the elution rate of 2BV/h was 87.32%, the elution rate of 3BV/h was 79.81%, and the elution rate of 4BV/h The rate is 76.49%. The elution rate is the largest when the speed is 2BV/h, so the elution speed is determined to be 2BV/h.
径高比考察Aspect-to-Height Ratio Inspection
取三根层析柱,分别称取20g、40g、60g(干重)经预处理的AB-8大孔吸附树脂,装柱,取柴胡提取液150ml、300ml、450ml(0.2g生药/ml),以1BV/小时的速度上样,放置2小时后,分别用水10BV、20%乙醇10BV洗脱,再用70%乙醇10BV洗脱,2BV/份收集70%乙醇洗脱液,测定洗脱液中柴胡总皂苷的含量。结果表明,三种径高比的洗脱率基本一致,说明径高比对洗脱率影响不大。Take three chromatography columns, weigh 20g, 40g, and 60g (dry weight) of pretreated AB-8 macroporous adsorption resin respectively, pack them into columns, and take 150ml, 300ml, and 450ml of Bupleurum extract (0.2g crude drug/ml) , loaded at a speed of 1BV/hour, after standing for 2 hours, eluted with 10BV of water and 10BV of 20% ethanol, and then eluted with 10BV of 70% ethanol, collected 70% ethanol eluate at 2BV/part, and measured the eluate The content of total saponins in Bupleurum. The results showed that the elution rates of the three diameter-to-height ratios were basically the same, indicating that the diameter-to-height ratio had little effect on the elution rate.
验证实验Verification experiment
取经预处理的AB-8大孔吸附树脂,装柱(三根,内径9.1cm,高度70cm,保留体积1500ml),分别取10000ml柴胡提取液(0.2g生药/ml),以1500ml/h的速度上样,放置2小时后,用去离子水15000ml以1500ml/h的速度洗脱,弃去洗脱液,再用20%乙醇15000ml以1500ml/h的速度洗脱,弃去洗脱液,用70%乙醇15000ml以3000ml/h的速度洗脱,收集洗脱液,减压回收乙醇,真空干燥,粉碎,得到3批柴胡总皂苷,测定含量。结果表明,三批柴胡总皂苷的得率基本一致,柴胡总皂苷的含量也相近,该实验的重复性较好。Take the pretreated AB-8 macroporous adsorption resin, pack it into columns (three, inner diameter 9.1cm, height 70cm, retention volume 1500ml), take 10000ml Bupleurum extract (0.2g crude drug/ml) respectively, with the speed of 1500ml/h Load the sample, and after standing for 2 hours, use 15000ml of deionized water to elute at a speed of 1500ml/h, discard the eluent, then use 15000ml of 20% ethanol to elute at a speed of 1500ml/h, discard the eluent, and use 15000ml of 70% ethanol was eluted at a speed of 3000ml/h, the eluent was collected, the ethanol was recovered under reduced pressure, vacuum dried, pulverized to obtain 3 batches of total saponins of Bupleurum, and the content was determined. The results showed that the yields of the three batches of total saponins were basically the same, and the contents of the total saponins were also similar, and the repeatability of the experiment was good.
表10验证实验结果Table 10 verification experiment results
最终确定柴胡总皂苷的纯化工艺为:取经预处理的AB-8大孔吸附树脂,装柱,取柴胡提取液(0.2g生药/ml)1BV,以1BV/小时的流速过AB-8大孔吸附树脂,静置2小时后,用去离子水10BV以1BV/小时的流速洗脱,弃去洗脱液,再用20%乙醇10BV以1BV/小时的流速清洗,弃去清洗液,用70%乙醇10BV以2BV/小时的速度洗脱,收集洗脱液,减压回收乙醇,浓缩至浸膏,60℃真空干燥,取出,粉碎,得到柴胡提取物。Finally, the purification process of Bupleurum saponins is determined as follows: take the pretreated AB-8 macroporous adsorption resin, pack it into a column, take 1BV of Bupleurum extract (0.2g crude drug/ml), and pass through AB-8 at a flow rate of 1BV/hour. Macroporous adsorption resin, after standing for 2 hours, eluted with 10BV of deionized water at a flow rate of 1BV/hour, discarded the eluent, and then washed with 10BV of 20% ethanol at a flow rate of 1BV/hour, discarded the cleaning solution, Elute with 70% ethanol 10BV at a rate of 2BV/hour, collect the eluate, recover ethanol under reduced pressure, concentrate to extract, vacuum-dry at 60°C, take out, and pulverize to obtain Bupleurum bupleuri extract.
三、胶囊的制备方法:Three, the preparation method of capsule:
根据药效筛选试验白芍总皂苷-柴胡总皂苷(9∶1)时药效最佳,取白芍总皂苷和柴胡总皂苷按上述比例混合均匀,对其进行堆密度、休止角的测定。According to the efficacy screening test, the total saponins of Paeoniae Alba-total saponins of Bupleurum (9:1) has the best drug effect, and the total saponins of Paeony and total saponins of Bupleurum are mixed uniformly according to the above ratio, and the bulk density and angle of repose are determined for it. Determination.
堆密度测定Bulk Density Determination
取以上混合物10g,置50ml量筒中,测定体积,计算堆密度。结果表明,本品的堆密度为0.8197g/ml。Take 10g of the above mixture, put it in a 50ml graduated cylinder, measure the volume, and calculate the bulk density. The results showed that the bulk density of this product was 0.8197g/ml.
休止角的测定Determination of angle of repose
对混合粉末的休止角进行测定,结果见表7。The angle of repose of the mixed powder was measured, and the results are shown in Table 7.
表7总皂苷混合物休止角测定结果Table 7 Total Saponin Mixture Angle of Repose Determination Result
结果表明,该粉末的流动性较好。The results show that the fluidity of the powder is better.
稀释剂用量的确定Determination of the amount of diluent
本品每粒应含柴胡总皂苷和白芍总皂苷混合物150mg,采用2号胶囊灌装。2号胶囊的体积为0.4ml,淀粉的堆密度为0.6514g/ml,因此,每粒胶囊还可以装150mg淀粉。取总皂苷混合物和淀粉按(1∶1)混合均匀,测定混合物的堆密度及休止角。结果表明,本品的流动性较好,淀粉可以作为本品的稀释剂。本品的堆密度为0.7752g/ml,每粒胶囊装300mg,选择2号胶囊,进行试装。结果确定采用2号胶囊进行分装。Each capsule of this product should contain 150mg of the mixture of total saponins of Bupleuri and total saponins of white paeony, and it is filled in No. 2 capsules. The volume of No. 2 capsule is 0.4ml, and the bulk density of starch is 0.6514g/ml, therefore, each capsule can also hold 150mg of starch. The total saponin mixture and starch were mixed uniformly (1:1), and the bulk density and angle of repose of the mixture were measured. The results show that the fluidity of this product is better, and starch can be used as a diluent of this product. The bulk density of this product is 0.7752g/ml, and each capsule is filled with 300mg. Choose No. 2 capsules for trial loading. As a result, it was determined that No. 2 capsules were used for subpackaging.
临界相对湿度测定Critical Relative Humidity Determination
为了防止药粉吸潮,测定了药粉的临界相对湿度,为控制分装车间的相对湿度提供参考依据。In order to prevent the powder from absorbing moisture, the critical relative humidity of the powder was measured to provide a reference for controlling the relative humidity in the packaging workshop.
解郁胶囊内容物吸湿平衡曲线Hygroscopic balance curve of Jieyu capsule contents
测定方法:取药粉2份,精密称定,打开称量瓶盖,分别放入湿度为58%的玻璃干燥器中,在25℃培养箱中放置,于1,2,3,6,9,12,24,36,48,72小时精密称定称量瓶与药粉的重量,计算吸湿百分率,绘制吸湿平衡曲线。结果表明,放置48小时后,供试品达到吸湿平衡。Determination method: Take 2 parts of the medicine powder, weigh them accurately, open the weighing bottle cap, put them into a glass desiccator with a humidity of 58%, place them in an incubator at 25°C, and store them at 1, 2, 3, 6, 9, 12, 24, 36, 48, and 72 hours Accurately weigh the weight of the weighing bottle and the powder, calculate the percentage of moisture absorption, and draw the moisture absorption balance curve. The results showed that after standing for 48 hours, the test product reached moisture absorption equilibrium.
临界相对湿度的测定Determination of critical relative humidity
测定方法:取药粉12份,分为2组,每组6份,每份约2g,精密称定,打开称量瓶盖,分别放入不同湿度的玻璃干燥器中,在25℃培养箱中放置,放置48h后,精密称定,计算吸湿率。绘制临界相对湿度曲线,结果表明,药粉的临界相对湿度为63%,因此在分装时,应将相对湿度控制在60%以下。Measuring method: Take 12 parts of the medicinal powder, divide them into 2 groups, 6 parts in each group, about 2g in each group, weigh them accurately, open the cap of the weighing bottle, put them into glass desiccators with different humidity respectively, and place them in a 25°C incubator Place it for 48 hours, weigh it accurately, and calculate the moisture absorption rate. The critical relative humidity curve is drawn, and the results show that the critical relative humidity of the medicinal powder is 63%, so when subpackaging, the relative humidity should be controlled below 60%.
取三批白芍总皂苷各540g,三批柴胡总皂苷各60g,混合均匀,分别加入600g淀粉,混合均匀,灌装于2号胶囊中。胶囊中含芍药苷的含量不得少于7.50%,白芍总皂苷的含量不得少于25.0%,柴胡皂苷d的含量不得少于0.50%,柴胡总皂苷的含量不得少于2.50%。Take three batches of total saponins of paeony, each 540g, three batches of total saponins of Bupleuri, each 60g, mix evenly, add 600g starch respectively, mix evenly, and fill in No. 2 capsules. The content of paeoniflorin in the capsule shall not be less than 7.50%, the content of total saponins of paeony shall not be less than 25.0%, the content of saikosaponin d shall not be less than 0.50%, and the content of total saikosaponins shall not be less than 2.50%.
四、本发明组合物配方比例筛选试验Four, the composition formula ratio screening test of the present invention
1、实验材料1. Experimental materials
1.1药品1.1 Drugs
上述柴胡提取物,上述白芍提取物,以0.5%CMC-Na为混悬剂,用高速均质机均质10min,使成混悬液,用前摇匀;The above-mentioned Bupleurum extract and the above-mentioned Radix Paeoniae Alba extract are suspended with 0.5% CMC-Na, homogenized by a high-speed homogenizer for 10 minutes, made into a suspension, and shaken before use;
盐酸氯米帕明片(诺华制药,批号X0026,25mg/片);Clomipramine hydrochloride tablets (Novartis Pharmaceuticals, batch number X0026, 25mg/tablet);
1.2实验动物1.2 Experimental animals
ICR小鼠,清洁级。雌雄各半,由浙江省实验动物中心提供,实验动物合格证号:浙医动字第2001001号。ICR mice, clean grade. Half male and half female, provided by Zhejiang Experimental Animal Center, experimental animal qualification certificate number: Zheyi Dongzi No. 2001001.
1.3主要仪器1.3 Main instruments
小鼠悬尾架(自制),电子秒表等。Mouse tail suspension (homemade), electronic stopwatch, etc.
2、分组及给药2. Grouping and administration
由于未见柴胡白芍提取物治疗抑郁症相关研究文献,根据经验拟定小鼠给药剂量为500mg/Kg.d(柴胡总皂苷加白芍总皂苷总量),阳性组给盐酸氯米帕明片,给药剂量20mg/Kg,正常组给0.5%CMC-Na溶液。给药组剂量方案见表8。Since there is no relevant research literature on the treatment of depression with Bupleuri Radix and Radix Paeoniae Alba extract, the dosage of mice is determined to be 500mg/Kg.d (the total saponins of Radix Bupleuri and total saponins of Radix Paeoniae Alba) based on experience, and the positive group is given clomipramine hydrochloride Tablets, dosage 20mg/Kg, normal group was given 0.5% CMC-Na solution. The dose regimen of the drug administration group is shown in Table 8.
表8提取物给药剂量方案设计Table 8 Design of dosage regimen for extract administration
3、实验方法3. Experimental method
3.1小鼠悬尾实验3.1 Mouse tail suspension test
小鼠连续灌胃给药7天,于末次灌胃1小时后,将小鼠尾端2cm处固定于水平杆上,使其呈倒挂状态,头部离台面约20cm,四周以板隔离动物视线,记录小鼠在6分钟内的不动时间。The mice were administered by gavage continuously for 7 days. One hour after the last gavage, the tail end of the mouse was fixed on a horizontal bar at 2 cm, so that it was in an upside-down state. , Record the immobility time of the mice within 6 minutes.
3.2小鼠强迫游泳实验3.2 Mice forced swimming test
先做预试验,将小鼠放入直径18cm,水深10cm的烧杯,水温保持25℃,小鼠游泳2分钟后,开始观察,观察持续4分钟,累计4分钟内小鼠在水中停止挣扎、呈漂浮状态、仅有细小的肢体运动以保持头部浮在水面的持续时间(不动时间),将不动时间超过120秒或低于60秒者小鼠剔除。将合格小鼠随机分组,连续灌胃7天,于末次灌胃1小时后,按预试验方法进行强迫游泳试验,累计4分钟内小鼠的不动时间。Do a preliminary test first, put the mice into a beaker with a diameter of 18cm and a water depth of 10cm, keep the water temperature at 25°C, swim the mice for 2 minutes, then start to observe, the observation lasts for 4 minutes, within 4 minutes, the mice stop struggling in the water and show signs of life. Floating state, only small limb movements to keep the head floating on the water (immobility time), the mice whose immobility time exceeds 120 seconds or less than 60 seconds are removed. Qualified mice were randomly divided into groups and gavaged continuously for 7 days. One hour after the last gavage, the forced swimming test was performed according to the pre-test method, and the immobility time of the mice within 4 minutes was accumulated.
4、实验结果4. Experimental results
4.1不同配方比例对小鼠体重的影响4.1 Effects of different formula ratios on the body weight of mice
末次灌胃给药后,称量各组小鼠体重,结果见表9。发现治疗组体重均较正常组和阳性组轻,除治疗组1和治疗组7外,均有显著差异。After the last oral administration, the mice in each group were weighed, and the results are shown in Table 9. It was found that the body weight of the treatment group was lighter than that of the normal group and the positive group, except for the treatment group 1 and the treatment group 7, there were significant differences.
表9不同配方比例对小鼠体重的影响 Table 9 The impact of different formula ratios on the body weight of mice
注:与正常组比较:*P<0.05,**P<0.01Note: Compared with the normal group: * P<0.05, ** P<0.01
4.2不同配方比例对小鼠悬尾不动时间的影响4.2 Effects of different formula ratios on the tail suspension time of mice
小鼠在悬尾状态下很快会出现绝望行为,表现为不再挣扎,呈现持续安静不动状态。从表10可见,除治疗组9外,所有给药组与正常组相比,均能明显缩短悬尾不动时间,其中治疗组8效果最好。In the state of tail suspension, the mouse will soon appear desperate behavior, showing that it no longer struggles, and presents a continuous quiet state. It can be seen from Table 10 that, except for treatment group 9, compared with the normal group, all drug administration groups can significantly shorten the tail suspension immobility time, and treatment group 8 has the best effect.
表10不同配方比例对小鼠悬尾不动时间的影响 Table 10 Effects of different formula ratios on the tail suspension time of mice
注:与正常组比较:*P<0.05,**P<0.01,***P<0.001Note: Compared with the normal group: * P<0.05, ** P<0.01, *** P<0.001
4.3不同配方比例对小鼠强迫游泳不动时间的影响4.3 Effects of different formula ratios on the immobility time of mice forced to swim
从表11可见,治疗组3、治疗组8和阳性组,与正常组相比,能明显缩短强迫游泳不动时间。It can be seen from Table 11 that compared with the normal group, the treatment group 3, treatment group 8 and positive group can significantly shorten the immobility time of forced swimming.
表11不同配方比例对小鼠强迫游泳不动时间的影响 Table 11 Effects of different formula ratios on the immobility time of mice forced to swim
注:与正常组比较:*P<0.05Note: Compared with normal group: * P<0.05
5、结论5 Conclusion
小鼠悬尾试验和小鼠强迫游泳试验是常用的抗抑郁药物筛选方法,且实验结果较可靠。实验结果表明,治疗组8(柴胡总皂苷∶白芍总皂苷=1∶9)抗抑郁疗效最佳,治疗组9(柴胡总皂苷∶白芍总皂苷=0∶10)抗抑郁疗效最差。所以,柴胡虽然量少,但起到关键性的作用,可是其他配方比例,甚至单用柴胡,抗抑郁疗效均不尽人意。由此可见,柴胡和白芍的配伍比例是影响其药理作用的关键性因素。实验中还发现,给药后治疗组体重较正常组和阳性组轻,提示可能有降脂减肥的功能。Mouse tail suspension test and mouse forced swimming test are commonly used antidepressant drug screening methods, and the experimental results are relatively reliable. The experimental results showed that treatment group 8 (total saponins of Bupleuri: total saponins of paeony = 1:9) had the best antidepressant effect, and treatment group 9 (total saponins of paeony: total saponins of paeony = 0:10) had the best antidepressant effect. Difference. Therefore, although the amount of Bupleurum is small, it plays a key role. However, other formula ratios, even Bupleurum alone, have unsatisfactory antidepressant effects. It can be seen that the compatibility ratio of Bupleurum and Radix Paeoniae Alba is a key factor affecting its pharmacological effects. In the experiment, it was also found that the weight of the treatment group after administration was lighter than that of the normal group and the positive group, suggesting that it may have the function of reducing fat and losing weight.
按最佳疗效治疗组8,确定解郁胶囊的配方比例为柴胡总皂苷∶白芍总皂苷=1∶9,小鼠用量为每日500mg/Kg,即柴胡总皂苷50mg/Kg、白芍总皂苷450mg/Kg。以体表面积换算,相当于成人每日服用解郁胶囊2000mg,即柴胡总皂苷200mg、白芍总皂苷1800mg,换算为生药量相当于柴胡4.8g,白芍58.7g。Treat group 8 according to the best curative effect, determine that the formula ratio of Jieyu capsule is total saponins of Bupleuri: total saponins of white paeony=1:9, and the dosage of mice is 500 mg/Kg every day, i.e. total saponins of Bupleurum 50 mg/Kg, white paeony Total paeony saponins 450mg/Kg. In terms of body surface area, it is equivalent to an adult taking 2000mg of Jieyu Capsules per day, namely 200mg of total saponins of Bupleurum and 1800mg of total saponins of Paeony. The amount of crude drugs converted into crude drugs is equivalent to 4.8g of Bupleurum and 58.7g of Paeoniae Alba.
五、本发明组合物的主要药效学研究Five, the main pharmacodynamic research of composition of the present invention
1、实验材料1. Experimental materials
1.1药品及试剂1.1 Drugs and reagents
上述柴胡提取物,上述白芍提取物,以0.5%CMC-Na为混悬剂,用高速均质机均质10min,使成混悬液,用前摇匀;The above-mentioned Bupleurum extract and the above-mentioned Radix Paeoniae Alba extract are suspended with 0.5% CMC-Na, homogenized by a high-speed homogenizer for 10 minutes, made into a suspension, and shaken before use;
盐酸氯米帕明片(诺华制药,批号X0026,25mg/片);Clomipramine hydrochloride tablets (Novartis Pharmaceuticals, batch number X0026, 25mg/tablet);
利血平注射液(广东邦民制药厂有限公司,批号090101,1mg/1ml);Reserpine injection (Guangdong Bangmin Pharmaceutical Factory Co., Ltd., batch number 090101, 1mg/1ml);
去甲肾上腺素(L-NE,SIGMA公司,批号A-9512);Norepinephrine (L-NE, SIGMA company, lot number A-9512);
多巴胺(DA,SIGMA公司,批号H8502)Dopamine (DA, SIGMA company, lot number H8502)
5-羟基吲哚乙酸(5-HIAA,SIGMA公司,批号H8876)5-Hydroxyindoleacetic acid (5-HIAA, SIGMA company, lot number H8876)
5-羟色胺(5-HT,SIGMA公司,批号H7752)5-hydroxytryptamine (5-HT, SIGMA company, lot number H7752)
醋酸、高氯酸、醋酸钠为分析纯试剂,甲醇为色谱纯试剂。Acetic acid, perchloric acid, and sodium acetate are analytically pure reagents, and methanol is chromatographically pure reagents.
1.2实验动物1.2 Experimental animals
ICR小鼠和SD大鼠,均为清洁级。雌雄各半,由浙江省实验动物中心提供,实验动物合格证号:浙医动字第2001001号。ICR mice and SD rats are clean grade. Half male and half female, provided by Zhejiang Experimental Animal Center, experimental animal qualification certificate number: Zheyi Dongzi No. 2001001.
1.3主要仪器1.3 Main instruments
小鼠悬尾架,自制,电击笼,自制。Mouse tail suspension, homemade, electric shock cage, homemade.
动物精神行为分析仪,荷兰NOLDUS公司,Ethovision3.0分析软件。Animal mental behavior analyzer, NOLDUS company in the Netherlands, Ethovision3.0 analysis software.
高效液相色分析系统,荧光检测器,美国VARIAN公司。High-performance liquid chromatography analysis system, fluorescence detector, American VARIAN company.
自动匀浆器,离心机,电子秒表,电子体温计等。Automatic homogenizer, centrifuge, electronic stopwatch, electronic thermometer, etc.
2、分组及给药2. Grouping and administration
2.1小鼠实验2.1 Mouse experiment
正常组:给0.5%CMC-Na溶液;Normal group: give 0.5% CMC-Na solution;
组合物小剂量组:250mg/kg,以0.5%CMC-Na均质混悬;Composition small dose group: 250mg/kg, homogeneously suspended with 0.5% CMC-Na;
组合物中剂量组:500mg/kg,以0.5%CMC-Na均质混悬;Dosage group in the composition: 500mg/kg, homogeneously suspended with 0.5% CMC-Na;
组合物大剂量组:750mg/kg,以0.5%CMC-Na均质混悬;Composition high-dose group: 750mg/kg, homogeneously suspended with 0.5% CMC-Na;
阳性组:盐酸氯米帕明片:20mg/kg,以0.5%CMC-Na均质混悬。Positive group: clomipramine hydrochloride tablets: 20 mg/kg, homogeneously suspended in 0.5% CMC-Na.
按照0.1ml/10g体积灌胃。According to the volume of 0.1ml/10g gavage.
2.2大鼠实验2.2 Rat experiment
正常组:给0.5%CMC-Na溶液;Normal group: give 0.5% CMC-Na solution;
模型组:给0.5%CMC-Na溶液;Model group: give 0.5% CMC-Na solution;
组合物小剂量组:125mg/kg,以0.5%CMC-Na均质混悬;Composition small dose group: 125mg/kg, homogeneously suspended with 0.5% CMC-Na;
组合物中剂量组:250mg/kg,以0.5%CMC-Na均质混悬;Dosage group in the composition: 250mg/kg, homogeneously suspended with 0.5% CMC-Na;
组合物大剂量组:375mg/kg,以0.5%CMC-Na均质混悬;Composition high-dose group: 375 mg/kg, homogeneously suspended with 0.5% CMC-Na;
阳性组:盐酸氯米帕明片:10mg/kg,以0.5%CMC-Na均质混悬。Positive group: clomipramine hydrochloride tablets: 10 mg/kg, homogeneously suspended in 0.5% CMC-Na.
按照1ml/100g体积灌胃。According to the volume of 1ml/100g gavage.
3、实验方法3. Experimental method
3.1小鼠自主活动试验3.1 Autonomous activity test of mice
小鼠连续灌胃解郁胶囊7天,于末次灌胃1小时后,放入75×75cm专用活动场地,并将场地平均分为25格,适应3分钟后,继续观察5分钟内小鼠的活动情况,以动物精神行为分析软件计算动物活动距离、边缘格活动率(即边缘格内活动距离占总活动距离的百分比)、两前肢离地次数、不动时间和中央格停留时间。Mice were fed Jieyu Capsules continuously for 7 days. One hour after the last gavage, they were placed in a 75×75cm special activity field, and the field was divided into 25 grids on average. After 3 minutes of adaptation, continue to observe the mice within 5 minutes For the activity situation, the animal's movement distance, the activity rate of the edge grid (that is, the percentage of the movement distance in the edge grid to the total activity distance), the number of times the two forelimbs are off the ground, the immobility time and the dwell time of the central grid are calculated with the animal mental behavior analysis software.
3.2小鼠悬尾实验3.2 Mouse tail suspension test
小鼠连续灌胃解郁胶囊7天,于末次灌胃1小时后后,将小鼠尾端2cm处固定于水平杆上,使其呈倒挂状态,头部离台面约10cm,四周以板隔离动物视线,记录小鼠在6分钟内的不动时间。Mice were given Jieyu Capsules for 7 days continuously. One hour after the last gavage, the mouse tail was fixed on a horizontal bar at 2 cm, so that it was in an upside-down state. The sight of the animal was recorded, and the immobility time of the mouse within 6 minutes was recorded.
3.3小鼠强迫游泳实验3.3 Mice forced swimming test
先做预试验,将小鼠放入直径18cm,水深10cm的烧杯,水温保持25℃,小鼠游泳2分钟后,开始观察,累计4分钟内小鼠在水中停止挣扎、呈漂浮状态、仅有细小的肢体运动以保持头部浮在水面的持续时间(不动时间),将不动时间超过120秒或低于60秒者小鼠剔除。将合格小鼠随机分组,连续灌胃7天,于末次灌胃1小时后,按预试验方法进行强迫游泳试验,累计4分钟内小鼠的不动时间。Do a preliminary test first, put the mice into a beaker with a diameter of 18cm and a water depth of 10cm, keep the water temperature at 25°C, swim the mice for 2 minutes, and then start to observe. The duration of small limb movements to keep the head floating on the water surface (immobility time), and the mice whose immobility time exceeds 120 seconds or is less than 60 seconds are removed. Qualified mice were randomly divided into groups and gavaged continuously for 7 days. One hour after the last gavage, the forced swimming test was performed according to the pre-test method, and the immobility time of the mice within 4 minutes was accumulated.
3.4大鼠拮抗利血平实验3.4 Antireserpine experiment in rats
SD大鼠连续灌胃解郁胶囊7天,于末次灌胃1小时后,皮下注射利血平3.5mg/kg,观察大鼠出现眼睑下垂的时间,并在注射利血平后2h、18h测定肛温。SD rats were given Jieyu Capsules continuously for 7 days, and 1 hour after the last gavage, subcutaneously injected reserpine 3.5mg/kg, observed the time of eyelid ptosis in rats, and measured it 2h and 18h after injection of reserpine Anal temperature.
3.5慢性不可预知的应激模型试验3.5 Chronic unpredictable stress model test
SD大鼠,实验前将大鼠单个置于盛有2/3自来水的塑料桶内(桶高55cm,水温20℃),游泳15min训练1次并熟悉环境。然后每天灌胃给药1次,参照文献方法,按下列顺序给予不良刺激:禁食不禁水48h(2d)-电击5min(36V,10mA,上下午各1次)(1d)-禁水不禁食24h(1d)-冰水游泳5min(1d)-夹尾悬吊5min(1d),完成1轮刺激共6d。恢复1d,第7d称体重后,每笼2只(个别3只)饲养,禁食,并喂以1%蔗糖水溶液,测定24h蔗糖水饮用量(奖赏反应)。第8d恢复正常供食和供水,第9d开始同样方法第二轮刺激。完成第2轮刺激后同法测定蔗糖水饮用量。次日,灌胃给药后30min,将大鼠置于水桶内,1min后开始记时,并用秒表记录5min内大鼠累计漂浮在水面上不动的时间,恢复一天后,将动物处死,取大脑海马组织测定单胺类神经递质(L-NE、DA、5-HIAA、5-HT)的含量。For SD rats, before the experiment, place the rats individually in a plastic bucket filled with 2/3 tap water (the height of the bucket is 55cm, Water temperature 20°C), swimming for 15 minutes for training once and getting familiar with the environment. Then intragastric administration once a day, according to the method in the literature, give adverse stimuli in the following order: fasting without water for 48 hours (2d)-electric shock for 5min (36V, 10mA, once in the morning and afternoon) (1d)-without water Eat for 24h (1d)-swim in ice water for 5min(1d)-tail suspension for 5min(1d), complete one round of stimulation for a total of 6d. After recovering for 1 day and weighing on the 7th day, 2 animals (3 individuals) were fed in each cage, fasted, and fed with 1% sucrose aqueous solution, and the drinking amount of sucrose water was measured for 24 hours (reward response). On the 8th day, the normal food and water supply was resumed, and on the 9th day, the second round of stimulation was started in the same way. After completing the second round of stimulation, the consumption of sucrose water was determined in the same way. On the next day, 30 minutes after intragastric administration, the rats were placed in a water bucket, and the time was started after 1 minute, and a stopwatch was used to record the accumulated floating time of the rats on the water surface within 5 minutes. After one day of recovery, the animals were put to death and taken. The contents of monoamine neurotransmitters (L-NE, DA, 5-HIAA, 5-HT) were determined in the hippocampal tissue of the brain.
由于单胺类神经递质容易被氧化,因此样品处理时必须低温和避光条件下进行。在冰台上尽快取出海马,用生理盐水冲洗,除去血液,滤纸拭干,称重。每只大鼠的海马约加1.0ml冰冷的0.4mol/L高氯酸溶液,在冰浴中用高速匀浆机匀浆,将海马组织匀浆液转入2.0mlEpendet离心管中,置冷冻离心机内以12000r/min离心15分钟,取上清液转移至1.0ml容量瓶中,用0.4mol/L高氯酸溶液定容至刻度,得样品溶液,备用。Since monoamine neurotransmitters are easily oxidized, sample processing must be carried out under low temperature and dark conditions. Take out the hippocampus as soon as possible on the ice platform, rinse with normal saline, remove the blood, dry it with filter paper, and weigh it. Add about 1.0ml of ice-cold 0.4mol/L perchloric acid solution to the hippocampus of each rat, homogenize with a high-speed homogenizer in an ice bath, transfer the hippocampal tissue homogenate into a 2.0ml Ependet centrifuge tube, and place in a refrigerated centrifuge Centrifuge at 12000r/min for 15 minutes, transfer the supernatant to a 1.0ml volumetric flask, and dilute to the mark with 0.4mol/L perchloric acid solution to obtain a sample solution for later use.
色谱条件:色谱柱:YMC-C18柱(250×4.6mm 5μm)。流动相0.1mol·L-1的醋酸钠(内含0.1mmol·L-1的EDTA-2Na),用Hac调节PH5.1,用0.45μm的微孔滤膜过滤,超声脱气,此缓冲液为流动相B,甲醇为流动相A,按比例9∶1等度洗脱,流速为1.0ml/min,进样10μL,发射波长330nm,激发波长290nm。柱温:30℃。Chromatographic conditions: Chromatographic column: YMC-C18 column (250×4.6mm 5μm). The mobile phase is 0.1mol L-1 sodium acetate (containing 0.1mmol L-1 EDTA-2Na), adjusted to pH 5.1 with Hac, filtered through a 0.45μm microporous membrane, and degassed by ultrasonic. Mobile phase B, methanol as mobile phase A, isocratic elution at a ratio of 9:1, flow rate 1.0ml/min, injection 10 μL, emission wavelength 330nm, excitation wavelength 290nm. Column temperature: 30°C.
4实验结果4 Experimental results
4.1组合物对正常小鼠自主活动的影响4.1 The influence of composition on normal mouse autonomic activity
表12可见,除小剂量组前肢离地次数低于正常组外,组合物对正常小鼠自主活动各项指标并无显著影响,提示组合物并非中枢兴奋药。It can be seen from Table 12 that, except that the number of forelimbs in the low-dose group is lower than that of the normal group, the composition has no significant impact on the indicators of normal mouse autonomic activity, suggesting that the composition is not a central nervous system stimulant.
表12组合物对正常小鼠自主活动的影响(n=10)The influence of table 12 compositions on normal mouse autonomic activity ( n=10)
注:与正常组比较:*P<0.05Note: Compared with normal group: * P<0.05
4.2组合物对正常小鼠悬尾不动时间的影响4.2 Effect of the composition on the tail suspension time of normal mice
表13可见,阳性组、组合物小剂量组和中剂量组,与正常组相比,能明显减少悬尾不动时间。It can be seen from Table 13 that the positive group, the low-dose group and the middle-dose group of the composition can significantly reduce the tail suspension time compared with the normal group.
表13组合物对小鼠悬尾不动时间的影响 The influence of table 13 compositions on mouse tail suspension time
注:与正常组比较:*P<0.05Note: Compared with normal group: * P<0.05
4.3组合物对小鼠强迫游泳不动时间的影响4.3 Effect of the composition on the immobility time of mice forced to swim
表14可见,阳性组、组合物小剂量组和中剂量组,与正常组相比,能明显减少强迫游泳不动时间。It can be seen from Table 14 that the positive group, the low-dose group and the middle-dose group of the composition, compared with the normal group, can significantly reduce the immobility time of forced swimming.
表14组合物对小鼠强迫游泳不动时间的影响 The impact of table 14 composition on the immobility time of mice's forced swimming
注:与正常组比较:*P<0.05Note: Compared with normal group: * P<0.05
4.4组合物对大鼠拮抗利血平的影响4.4 Effects of Compositions on Reserpine Antagonism in Rats
利血平具有排空脑内单胺神经递质的作用,能引起大鼠眼睑下垂,并引起体温明显下降。表15可见,和正常大鼠相比,组合物能明显延长大鼠注射利血平后眼睑下垂出现时间,并且呈现一定的量效关系。同时,与模型组相比,组合物能使大鼠体温显著恢复。Reserpine has the effect of emptying the monoamine neurotransmitter in the brain, can cause ptosis of the eyelids in rats, and cause a significant drop in body temperature. It can be seen from Table 15 that, compared with normal rats, the composition can significantly prolong the occurrence time of eyelid ptosis after the rats are injected with reserpine, and presents a certain dose-effect relationship. At the same time, compared with the model group, the composition can significantly restore the body temperature of rats.
表15组合物对大鼠拮抗利血平的影响 The influence of table 15 composition on rat antagonism reserpine
注:与模型组比较:*P<0.05,**P<0.01,***P<0.001Note: Compared with the model group: * P<0.05, ** P<0.01, *** P<0.001
与正常组比较:#P<0.05Compared with normal group: #P<0.05
4.5组合物对慢性抑郁模型大鼠的影响4.5 Effects of Composition on Chronic Depression Model Rats
经多种不良刺激联合作用后大鼠体重增长速度明显下降,一般状态略差,皮毛蓬松,活动减少。表16可见,在第1轮刺激的7d中体重增长与正常组比较,明显减缓,大剂量组甚至出现体重减轻的现象。第2轮刺激的7d中,造模各组体重增长较第1轮有所改善,但仍低于正常组体重的增长。与模型组相比,给药组大鼠的体重在第1轮刺激中,大剂量组明显低于模型组,其余各组与模型组未见明显差异。至第2轮刺激完成后给药组大鼠的体重与模型组比较均无明显差异。After the combination of various adverse stimuli, the rats' body weight growth rate decreased significantly, their general condition was slightly worse, their fur was fluffy, and their activities decreased. It can be seen from Table 16 that in the 7 days of the first round of stimulation, the weight gain was significantly slowed down compared with the normal group, and the high-dose group even lost weight. During the 7 days of the second round of stimulation, the weight gain of each modeling group was improved compared with the first round, but still lower than that of the normal group. Compared with the model group, the body weight of the rats in the administration group was significantly lower than that of the model group in the first round of stimulation, and there was no significant difference between the other groups and the model group. After the completion of the second round of stimulation, there was no significant difference in the body weight of the rats in the administration group compared with the model group.
糖水饮用量反映动物对奖赏的反应程度,抑郁症的模型动物对奖赏的反应性下降,糖水饮用量显著降低。表17可见,本实验中模型组大鼠的饮水量在经过第1轮和第2轮刺激后仅为正常组的75%和66%。组合物可以明显增加模型动物的糖水饮用量,提高对奖赏的反应,并有一定的剂量关系。The amount of sugar water consumed reflects the degree of response of animals to rewards, and the response of depression model animals to rewards decreased, and the amount of sugar water consumed was significantly reduced. It can be seen from Table 17 that the water consumption of the rats in the model group in this experiment was only 75% and 66% of the normal group after the first and second rounds of stimulation. The composition can obviously increase the drinking amount of sugar water of model animals and improve the response to reward, and there is a certain dose relationship.
当大鼠进入一个有限空间使之游泳,开始时拼命游动试图逃脱,经多次努力失败后出现绝望行为,表现为漂浮不动状态,实际是动物放弃逃脱的希望,属于行为绝望,静止不动时间长短可以代表大鼠绝望(抑郁)的程度。表18可见,模型组大鼠的游泳不动时间比正常组大鼠明显增加,组合物对慢性抑郁模型大鼠游泳绝望行为有明显的对抗作用,能使游泳不动时间明显缩短,量效关系明确。大剂量组游泳不动时间比模型组降低58%,中小剂量组也明显缩短游泳不动时间。表19可见,解郁胶囊能明显提高慢性抑郁模型动物海马中单胺类神经递质(L-NE、DA、5-HIAA、5-HT)的水平,初步阐明了提高脑内单胺类神经递质水平是解郁胶囊抗抑郁作用机理之一。When a rat enters a limited space to make it swim, it swims desperately at the beginning and tries to escape. After repeated efforts and failures, it appears a desperate behavior, which is manifested as a floating state. In fact, the animal gives up the hope of escape, which belongs to the behavior of despair and immobility. The length of the movement time can represent the degree of despair (depression) of the rat. It can be seen from Table 18 that the swimming immobility time of the model group rats is significantly increased compared with the normal group rats, and the composition has obvious antagonism to the swimming desperate behavior of the chronic depression model rats, and can significantly shorten the swimming immobility time, the dose-effect relationship clear. The immobility time of swimming in the high-dose group was reduced by 58% compared with the model group, and the immobility time of swimming in the small and medium dose group was also significantly shortened. It can be seen from Table 19 that Jieyu Capsules can significantly improve the levels of monoamine neurotransmitters (L-NE, DA, 5-HIAA, 5-HT) in the hippocampus of chronic depression model animals, and preliminarily clarified the improvement of monoamine neurotransmitters in the brain. Transmitter level is one of the antidepressant mechanism of Jieyu Capsules.
表16组合物对慢性抑郁模型大鼠体重影响 Table 16 composition influences the body weight of chronic depression model rats
注:与正常组比较:##P<0.01,###P<0.001Note: Compared with normal group: ##P<0.01, ###P<0.001
与模型组比较:**P<0.01Compared with the model group: ** P<0.01
表17组合物对慢性抑郁模型大鼠奖赏反应的影响 Table 17 Effect of composition on reward response in chronic depression model rats
注:与正常组比较:#P<0.05,##P<0.01Note: Compared with normal group: #P<0.05, ##P<0.01
与模型组比较:*P<0.05,**P<0.01Compared with the model group: * P<0.05, ** P<0.01
表18组合物对慢性抑郁模型大鼠强迫游泳不动时间的影响 Table 18 Effects of Compositions on Forced Swimming Immobility Time in Chronic Depression Model Rats
注:与正常组比较:#P<0.05Note: Compared with normal group: #P<0.05
与模型组比较:*P<0.05,***P<0.001Compared with the model group: * P<0.05, *** P<0.001
表19组合物对慢性抑郁模型大鼠海马中单胺类神经递质的影响 Table 19 Effects of compositions on monoamine neurotransmitters in the hippocampus of chronic depression model rats
注:与正常组比较:#P<0.05,##P<0.01,###P<0.001Note: Compared with normal group: #P<0.05, ##P<0.01, ###P<0.001
与模型组比较:*P<0.05,**P<0.01,***P<0.001Compared with the model group: * P<0.05, ** P<0.01, *** P<0.001
5药效学试验总结5 Summary of Pharmacodynamic Tests
实验采用小鼠悬尾实验、小鼠强迫游泳实验、大鼠拮抗利血平实验、大鼠慢性不可预知的应激模型试验等公认的抗抑郁动物试验方法进行组合物药效学研究,同时应用动物精神行为分析系统观察了组合物对动物自主活动的影响。结果证实,组合物能够明显缩短小鼠悬尾不动时间,小鼠强迫游泳不动时间。对大剂量利血平造模大鼠,能够明显延长眼睑下垂出现时间,明显拮抗利血平引起的体温下降。对慢性抑郁模型大鼠,组合物能明显提高模型大鼠对蔗糖水的奖赏反应,能明显缩短模型大鼠强迫游泳不动时间,其作用与盐酸氯米帕明接近。通过开场试验,证实组合物对正常动物自主活动并无明显影响,说明组合物并非中枢兴奋类药物。通过测定慢性抑郁模型大鼠大脑海马区组织中的单胺类神经递质含量,证实组合物能明显提高模型动物海马中L-NE、DA、5-HIAA、5-HT的水平,初步阐明了提高脑内单胺类神经递质水平是组合物抗抑郁作用机理之一。In the experiment, recognized antidepressant animal test methods such as mouse tail suspension test, mouse forced swimming test, rat antagonism reserpine test, and rat chronic unpredictable stress model test were used to study the pharmacodynamics of the composition. The Animal Psychobehavioral Analysis System observes the effect of compositions on the voluntary activities of animals. The results confirm that the composition can obviously shorten the immobility time of the tail suspension of mice and the immobility time of mice forced to swim. For rats modeled with high-dose reserpine, it can significantly prolong the appearance time of eyelid ptosis, and obviously antagonize the drop in body temperature caused by reserpine. For chronic depression model rats, the composition can obviously improve the reward response of the model rats to sucrose water, and can obviously shorten the immobility time of the model rats in forced swimming, and its effect is close to that of clomipramine hydrochloride. Through the open field test, it is confirmed that the composition has no obvious influence on normal animal autonomic activity, indicating that the composition is not a central nervous system excitatory drug. By measuring the content of monoamine neurotransmitters in the hippocampal tissue of the chronic depression model rats, it was confirmed that the composition can significantly increase the levels of L-NE, DA, 5-HIAA, and 5-HT in the hippocampus of the model animals, and preliminarily clarified the Improving the level of monoamine neurotransmitters in the brain is one of the antidepressant action mechanisms of the composition.
药效学试验中,对正常小鼠的悬尾实验和强迫游泳实验结果,并未发现剂量和疗效之间的相关性,且均以中剂量组效果最佳。而在需要造模的大鼠拮抗利血平实验和大鼠慢性不可预知的应激模型试验中,组合物均呈现明显的量效关系。可能由于组合物在病理状态下更容易发挥药效有关。同时也发现,组合物对动物体重增长也有一定的抑制作用,是否会影响动物的脂质代谢,也有待于进一步研究。In the pharmacodynamics test, no correlation between dosage and curative effect was found in the tail suspension test and forced swimming test of normal mice, and the middle dose group had the best effect. However, in the rat antagonism reserpine experiment that needs to be modeled and the rat chronic unpredictable stress model experiment, the composition shows an obvious dose-effect relationship. It may be related to the fact that the composition is more likely to exert its medicinal effect in a pathological state. At the same time, it is also found that the composition also has a certain inhibitory effect on the weight gain of animals, and whether it will affect the lipid metabolism of animals remains to be further studied.
药效学实验表明,组合物小剂量组即有明显抗抑郁药理作用,按体表面积换算,相当于成人每日服用组合物1000mg,即柴胡总皂苷100mg、白芍总皂苷900mg,换算为生药量相当于柴胡2.4g,白芍29.4g。机理研究表明,小剂量组对模型动物海马中的神经递质并无明显的提高作用,提示组合物抗抑郁可能有其他的作用机理,多靶点共同起效。Pharmacodynamic experiments show that the small dose group of the composition has obvious antidepressant pharmacological effects, which is equivalent to an adult taking 1000 mg of the composition per day, that is, 100 mg of total saponins of Bupleuri and 900 mg of total saponins of paeony, converted into crude drugs The amount is equivalent to 2.4g of Bupleurum and 29.4g of Radix Paeoniae Alba. Mechanism studies have shown that the low-dose group has no significant effect on increasing the neurotransmitters in the hippocampus of model animals, suggesting that the antidepressant composition of the composition may have other mechanisms of action, and multiple targets work together.
六、本发明组合物的毒理学研究:Six, the toxicology research of composition of the present invention:
1、急性毒性试验:由于该组合物毒性很低,无法测出LD50,而测得小鼠最大给药量为7.5g/kg(组合物/体重),相当于临床成人用药剂量(按体表面积换算)的1000倍,连续观察10天,未见明显毒性反应。1. Acute toxicity test: because the toxicity of the composition is very low, the LD50 cannot be measured, and the maximum administration dose of the mouse is 7.5g/kg (composition/body weight), which is equivalent to the dosage for clinical adults (according to the body surface area) Conversion) 1000 times, continuous observation for 10 days, no obvious toxic reaction.
2、长期毒性试验:大鼠灌胃组合物,大剂量组7.5g/kg为临床成人用药剂量的1000倍,中剂量2.5g/kg为临床成人用药剂量的333倍,小剂量0.75g/kg为临床成人用药剂量的100倍。连续灌胃给药6个月,未见大鼠在大剂量状况下出现死亡情况,也未见明显毒性反应,说明该组合物安全性较大。2. Long-term toxicity test: the composition was administered to rats, the large dose group 7.5g/kg is 1000 times the clinical adult dose, the medium dose 2.5g/kg is 333 times the clinical adult dose, and the small dose 0.75g/kg It is 100 times of the clinical dosage for adults. After continuous intragastric administration for 6 months, no rats were found to die under high-dose conditions, and no obvious toxic reactions were seen, indicating that the composition is relatively safe.
本发明组合物由柴胡和白芍组方而成,方中柴胡轻清,长于疏达走窜,辛散善行,为疏肝理气,开郁结退热之佳品;白芍之功以补养阴血见长,又能柔肝平肝,缓急止痛,清解虚热。二药相伍,柴胡得白芍之柔,行肝气而不致疏泄太过,耗肝之体;白芍得柴胡之散,补肝血而不致郁遏气阴,碍肝之用,共奏疏肝、解郁和解表里止痛之功。既能疏肝解郁,以治肝用之不达,又能柔肝益阴以补肝体,为体用兼顾之最佳配伍。The composition of the present invention is composed of Radix Bupleurum and Radix Paeoniae Alba. In the formula, Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Bupleuri to Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Bupleuri and Radix Radix Radix Radix Radix Radix Radix Paeoniae. Yin blood is good at growing, and it can soften the liver and calm the liver, relieve spasm and relieve pain, and clear away asthenic heat. The combination of the two medicines, Bupleurum to obtain the softness of Radix Paeoniae Alba, promotes liver qi without excessive dredging and exhausting the liver body; Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Radix Paeoniae Alba nourishes liver blood without causing stagnation of qi and yin, hindering the function of the liver. It plays the functions of soothing the liver, relieving depression and relieving pain from the outside and inside. It can not only soothe the liver and relieve stagnation, so as to treat the insufficiency of the liver, but also soften the liver and replenish yin to nourish the liver and body. It is the best combination for both body and function.
本发明经现代制药工艺提取柴胡总皂苷和白芍总皂苷,按一定配伍比例制成解郁胶囊,具有明确的药用有效部位和明确的疗效,且无明显毒副反应。本发明组合物制备方法工艺稳定,操作可行,提取率高,纯度高,环境污染小,适合工业化生产,能取得较好的社会效益和经济效益。The invention extracts total saponins of Bupleuri and total saponins of paeony through modern pharmaceutical technology, and prepares Jieyu capsules according to a certain compatibility ratio, has clear medicinal effective parts and clear curative effects, and has no obvious toxic and side effects. The preparation method of the composition of the invention is stable in process, feasible in operation, high in extraction rate, high in purity, less in environmental pollution, suitable for industrial production, and capable of achieving better social and economic benefits.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110222956 CN102283910B (en) | 2011-08-05 | 2011-08-05 | Chinese medicinal composition with anti-depression effect and preparation and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110222956 CN102283910B (en) | 2011-08-05 | 2011-08-05 | Chinese medicinal composition with anti-depression effect and preparation and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102283910A true CN102283910A (en) | 2011-12-21 |
| CN102283910B CN102283910B (en) | 2013-04-17 |
Family
ID=45330846
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110222956 Active CN102283910B (en) | 2011-08-05 | 2011-08-05 | Chinese medicinal composition with anti-depression effect and preparation and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102283910B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552436A (en) * | 2012-01-10 | 2012-07-11 | 上海市中医医院 | Medicine for treating anxiety and depressive disorder as well as application of medicine |
| CN111375041A (en) * | 2018-12-30 | 2020-07-07 | 鲁南制药集团股份有限公司 | Traditional Chinese medicine composition for treating depression and preparation method thereof |
| CN113813278A (en) * | 2021-11-10 | 2021-12-21 | 昆明理工大学 | New uses of saikosaponin D |
| CN114796297A (en) * | 2022-05-09 | 2022-07-29 | 南通大学 | Application of elecampane and radix bupleuri composition in preparation of antidepressant |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1883638A (en) * | 2006-05-31 | 2006-12-27 | 朱鸿龙 | Compound medicine for treating depression and method for preparing same |
| CN101579375A (en) * | 2009-06-10 | 2009-11-18 | 中国人民解放军第三○二医院 | Extract of bupleurum, preparation method and application thereof |
-
2011
- 2011-08-05 CN CN 201110222956 patent/CN102283910B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1883638A (en) * | 2006-05-31 | 2006-12-27 | 朱鸿龙 | Compound medicine for treating depression and method for preparing same |
| CN101579375A (en) * | 2009-06-10 | 2009-11-18 | 中国人民解放军第三○二医院 | Extract of bupleurum, preparation method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| 王树桂 等: "抑郁症药物治疗进展", 《中国民族民间医药》 * |
| 胥庆华: "《中药药对大全》", 31 March 1996 * |
| 苏孝共等: "白芍与柴胡不同比例配伍芍药苷水煎出量的比较", 《中国现代应用药学》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102552436A (en) * | 2012-01-10 | 2012-07-11 | 上海市中医医院 | Medicine for treating anxiety and depressive disorder as well as application of medicine |
| CN102552436B (en) * | 2012-01-10 | 2014-05-07 | 上海市中医医院 | Medicine for treating anxiety and depressive disorder as well as application of medicine |
| CN111375041A (en) * | 2018-12-30 | 2020-07-07 | 鲁南制药集团股份有限公司 | Traditional Chinese medicine composition for treating depression and preparation method thereof |
| CN111375041B (en) * | 2018-12-30 | 2022-07-01 | 鲁南制药集团股份有限公司 | Traditional Chinese medicine composition for treating depression and preparation method thereof |
| CN113813278A (en) * | 2021-11-10 | 2021-12-21 | 昆明理工大学 | New uses of saikosaponin D |
| CN114796297A (en) * | 2022-05-09 | 2022-07-29 | 南通大学 | Application of elecampane and radix bupleuri composition in preparation of antidepressant |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102283910B (en) | 2013-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106692297B (en) | Composition for assisting in reducing blood sugar and preparation method and application thereof | |
| CN102038701B (en) | Anti-depression application of albiflorin | |
| CN101890082A (en) | A group of pharmaceutical composition and preparation method for treating depression | |
| CN103417749B (en) | A kind of preparation method of Herba Violae extract and the application in hypoglycemic medicine thereof | |
| WO2009000145A1 (en) | Use and preparation of paeoniflorin and the composition thereof | |
| CN101347524A (en) | Traditional Chinese medicine composition for treating depression and preparation method thereof | |
| CN102283910A (en) | Chinese medicinal composition with anti-depression effect and preparation and preparation method thereof | |
| EP4190342A1 (en) | Traditional chinese medicine composition having mental relief and antidepressant effects and preparation method therefor | |
| CN103191198A (en) | Rhizoma corydalis extract as well as preparation method and use thereof | |
| CN104224811A (en) | Salvia miltiorrhiza medicine and preparation method thereof | |
| CN104546995B (en) | A kind of medicinal usage of emblic extract | |
| CN102125575A (en) | Application of albiflorin in resisting Parkinson's disease | |
| CN103169788A (en) | Chinese date leaf extractive and application thereof in preparation of medicament or health food for preventing and treating liver injury | |
| CN105687441A (en) | Application of litchi rind polyphenol in medicines for treating hyperglycemia and insulin resistance | |
| CN101347562A (en) | Anti-depression medicament as well as preparation method and application thereof | |
| CN114209739A (en) | Application of a Pulsatilla officinalis extract in the preparation of antidepressant drugs | |
| CN104055812B (en) | A kind of composition and preparation method and purposes with antidepressant effect | |
| CN101468155A (en) | Chinese medicinal composition for treating dementia, as well as preparation method, preparation and use thereof | |
| CN111773273A (en) | Total flavonoids of Privet stout, preparation method and application | |
| CN100348228C (en) | New use of powder for regulating liver and spleen and its active part | |
| CN102861117A (en) | Composition containing Chinese medicine active ingredients and application thereof | |
| CN101904894B (en) | Application of lamiophlomis rotate total glycosides in preparing medicines | |
| CN104491075A (en) | Refined part of total gardenia crocin with anti-depression effect as well as preparation method and application of refined part | |
| CN101234103B (en) | Total coumarin angelica dahurica composition | |
| CN109045240B (en) | Traditional Chinese medicine composition of Gaocheng preparation, preparation method, detection method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |